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ABSTRACT OF THESIS 
 
BEHAVIORAL EFFECTS OF ESTROGEN RECEPTOR BETA 
ACTING LOCALLY TO REGULATE THE EXPRESSION OF 
TRYPTOPHAN HYDROXYLASE 2 (TPH2) IN SEROTONERGIC 
NEURONS OF THE DORSAL RAPHE NUCLEI 
 
Affective disorders often involve serotonin (5-HT)-related dysfunctions and 
are twice as common in women than men. Interactions between estrogen and 
the brain 5-HT system have long been proposed to contribute to sex differences 
in mood and anxiety disorders, but the mechanisms underlying this phenomenon 
have yet to be revealed. Estrogen signaling is mediated by two different 
receptors termed estrogen receptor alpha and estrogen receptor beta.  While 
estrogen receptor alpha (ERalpha) has mainly reproductive responsibilities, in 
brain, estrogen receptor beta (ERbeta) has been shown to attenuate anxiety- and 
despair-like behaviors in rodent models. However, little is known about ERbeta 
regulation of function in the brainstem raphe nuclei. The raphe nuclei are the 
main 5-HT system of the brain, and projections from the dorsal raphe nuclei 
(DRN) innervate many important forebrain and limbic areas. The work presented 
in this thesis addressed the possibility that ERbeta may be involved in the 
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regulation of 5-HT gene expression specifically in DRN neurons. My studies 
examined the effects of systemic versus local, intracerebral application of the 
selective ERbeta agonist diarylpropionitrile (DPN) and the nonselective ER-
ligand estradiol (E) on tryptophan hydroxylase 2 (TPH2) mRNA expression within 
the DRN of female rats. TPH2 is the brain-specific, rate-limiting enzyme 
catalyzing 5-HT synthesis, and is expressed in every 5-HT neuron. Thus, it 
provides an excellent tool to assess the capacity for 5-HT production with the 
DRN. In these studies, TPH2 mRNA expression was assessed via in situ 
hybridization. In addition, relevant behavioral parameters were tested in all 
animals to evaluate each compound’s effect on two closely related, but yet 
different mental states, anxiety-like and despair-like behavior.  
Both, chronic systemic and chronic local DPN administration to   
ovariectomized (OVX) female rats significantly enhanced TPH2 mRNA 
expression in mid- and caudal subregions of the DRN after 8 days of treatment. 
Respective controls received systemic vehicle (27% hydroxypropyl-beta-
cyclodextrin) or blank control pellets. Local application of DPN caused a stronger 
effect than systemic drug delivery. Chronic local delivery of E (0.5 µM) increased 
TPH2 mRNA expression in the same subregions of the DRN as did DPN, but its 
overall effect was weaker compared to the selective ERbeta agonist. 
Interestingly, while systemic DPN-administration confirmed the anxiolytic nature 
of ERbeta in two separate anxiety tests (elevated plus maze and open field test), 
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the effect was lost when DPN was delivered locally. However, local DPN- as well 
as E-treatment both resulted in attenuated despair-like behavior, as measured in 
the forced-swim test. Chapter 3 describes the experimental design, results and 
interpretation of these studies in depth. 
Taken together, my data indicate that local actions of ERbeta agonist onto 
DRN neurons are sufficient to decrease despair-like behavior, whereas ERbeta 
stimulation of other brain regions is necessary to alter anxiety-like behaviors. 
Correspondingly, ERbeta acts locally to control TPH2 mRNA expression and 
presumably 5-HT synthesis in the certain subregions of the rat DRN. These 
results suggest an important role of ERbeta for regulating cellular events in the 
female DRN, and offer new opportunities for therapeutic treatments of depressive 
disorders. 
 
Nina Caroline Donner 
Department of Biomedical Sciences 
Colorado State University 
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About one of five Americans suffers from at least one episode of major 
depressive disorder (MDD) during their life (Kessler et al., 1994; Varghese and 
Brown, 2001; Bloom, 2004). Furthermore, the prevalence for the incidence, 
duration, gravity and reoccurrence of depression is twice as high in women as in 
men (Earls, 1987; Nolen-Hoeksema, 1987). An alteration in serotonin (5-HT) 
neurotransmission is the leading hypothesis regarding the pathophysiology 
underlying MDD (Arango et al., 2002; Mann, 2003; Lesch, 2004). Other 
neuropsychiatric disorders, such as schizophrenia (Veenstra-VanderWeele et al., 
2000), autism (Veenstra-VanderWeele and Cook, 2004), aggression and suicidal 
behavior (Arango et al., 2003), and attention deficit disorder (Gainetdinov et al., 
1999; Quist and Kennedy, 2001), are also related to dysfunctions of the brain 5-
HT system. Current antidepressants target the brain 5-HT system indirectly by 
inhibiting either the 5-HT transporter (SERT) or the monoamine oxidase (MAO), 
or by binding to 5-HT receptors on target neurons. However, the fact that 
tryptophan hydroxylase 2 (TPH2) itself – the brain-specific enzyme that catalyzes 
the rate-limiting step in 5-HT synthesis (Walther et al., 2003; Zhang et al., 2004) 
– is greatly associated with neuropsychotic disorders (Zill et al., 2004; Zhang et 
al., 2005; Bach-Mizrachi et al., 2006; Harvey et al., 2007; Maron et al., 2007) has 
not been paid proper regard yet. TPH2 could, in fact, provide the most direct 
target of the brain 5-HT system. Prior to the discovery of TPH2 (Walther et al., 
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2003), researchers either measured TPH1, the enzyme that mainly catalyzes the 
hydroxylation of tryptophan in the periphery and the pineal gland (Patel et al., 
2004), or they did not discriminate between the two isoforms (Singh et al., 1990; 
Boularand et al., 1995; Pecins-Thompson et al., 1996; Chamas et al., 1999; Lu et 
al., 1999; Rotondo et al., 1999). While these earlier studies are still of great 
value, they need to be interpreted with regard to the fact that there have always 
been two different genes each coding for one of the two isoforms. TPH1 is the 
non-brain-specific tryptophan hydroxylase, and its expression in the brain, 
including the raphe nuclei as the main site of 5-HT synthesis in the brain with 
projections to numerous forebrain areas (Abrams et al., 2004), is limited 
compared to TPH2 (Malek et al., 2005). Although a recent study drew attention to 
the potential involvement of TPH1 in the stress-reactivity of the dorsal raphe 5-
HT system (Abumaria et al., 2008), TPH2 may be the preferable isoform to target 
in order to upregulate 5-HT synthesis due to its predominant expression in 5-HT 
neurons. 
Ovarian hormones have often been implicated in modulation of 5-HT 
function (Joffe & Cohen 1998; McEwen & Alves 1999; Bethea et al. 1998), and 
among ovarian steroids, changing estrogen levels are thought to have the 
greatest effect on mood. Postpartum depression, as well as premenstrual 
syndrome (PMS), premenstrual dysphoric disorder (PMDD) and menopause 
depression are all associated with a sudden drop in circulating estrogen 
(Rubinow 1992; Halbreich et al. 1995; Buckwalter et al. 2001). The genomic 
actions of estrogen are accomplished by two distinct receptor systems, estrogen 
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receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) (Green et al., 
1986). Relevant literature has reported significant presence of ERbeta 
specifically in the dorsal raphe nuclei (DRN) of mammals (Shughrue et al., 
1997a; Alves et al., 1998; Gundlah et al., 2001; Mitra et al., 2003; Sheng et al., 
2004; Nomura et al., 2005; Vanderhorst et al., 2005), suggesting a potential role 
for ERbeta in the regulation of TPH2 gene expression (Pecins-Thompson et al., 
1996; Lu et al., 1999; Hiroi et al., 2006). Furthermore, various rodent models 
have been used to show that ERbeta agonists attenuate anxiety- and despair-like 
behaviors (Krezel et al., 2001; Imwalle et al., 2005; Lund et al., 2005; Rocha et 
al., 2005). Considering the importance of 5-HT systems for emotional stability, I 
therefore proposed to investigate the hypothesis that ERbeta is involved in the 
regulation of 5-HT-neuronal gene expression and consequently in the modulation 
of emotionality.  
The overall goal of my thesis research was to determine the function of 
ERs in the brainstem DRN, specifically to elucidate the neuronal and behavioral 
role of ERbeta in the regulation of serotonergic neurons in the DRN. The specific 
aim was to determine the effects of chronic systemic versus chronic local 
administration of estrogen or ERbeta selective agonist on anxiety and despair-
like behavior and on TPH2 mRNA expression within the DRN.  
In one experiment, female ovariectomized (OVX) Sprague-Dawley rats 
were either subcutaneously (s.c.) injected with selective ERbeta agonist 
diarylpropionitrile (DPN) or vehicle. In a second experiment, female OVX 
Sprague-Dawley rats were stereotaxically implanted, bilaterally, with small wax-
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pellets to deliver DPN or E site-specifically to the DRN. Unoperated and animals 
receiving blank pellets served as controls. All animals were tested for anxiety-like 
behavior on the elevated plus maze (EPM) and in the open field (OF). The 
animals’ active versus passive stress-coping strategies were analyzed in the 
forced-swim test (FST), an established test model for antidepressants and 
despair behavior. TPH2 mRNA levels were measured using in situ hybridization. 
My hypothesis was that local, 5-HT-neuronal ERbeta activation directly regulates 
the synthesis of TPH2, and that estradiol (E) may have a gradually different 
effect. I also expected the systemic and the local DPN-treatment to attenuate 
both anxiety- and despair-like behavior.    





5-HT AND ITS ROLE IN DEPRESSIVE DISORDERS 
A. THE METABOLISM OF TRYPTOPHAN 
The monoamine 5-HT is a key neurotransmitter of the brain (Cooper et al., 
2003). It is derived from the amino acid tryptophan, and because tryptophan itself 
cannot cross the blood brain barrier it is taken up into the brain via a non-
selective large amino acid transporter, LAT1 (Duelli et al., 2000; Killian and 
Chikhale, 2001), operating at the surface of the brain capillary endothelial cells. 
Only about 1% of the circulating tryptophan enters the brain, and on its way in it 
has to compete with all other large neutral amino acids (Baumann, 1979; Filippini 
et al., 1996; Allegri, 2003). Tryptophan is one of the eight essential amino acids 
that the human body cannot synthesize on its own, but must be absorbed from 
our food (Sidransky, 1985, 2002; Sarubin-Fragakis and American Dietetic 
Association., 2003; Davis, 2006). In fact, the so called “5-HT depletion studies” 
(Salomon et al., 1993; Delgado et al., 1994) - in which patients that were subject 
to a tryptophan-free diet showed severe downregulation of the peripheral and 
central 5-HT system - were the first to indicate a causal connection of 5-HT and 
the pathophysiology of many psychiatric disorders, most importantly depression.  
Once in the extracellular fluid of the brain, tryptophan is transported into 5-
HT neurons via a high-affinity neuronal tryptophan transporter. In the cytosol of 
the serotonergic neuron, tryptophan is hydroxylized at the 5-position by the rate-
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limiting enzyme of serotonin biosynthesis, neuronal tryptophan-hydroxylase, also 
called TPH2 (Walther et al., 2003; Zhang et al., 2004). For biochemical details 
see Fig. 1. In peripheral tissue, including the pineal gland, this step is performed 
by TPH1, the peripheral isoform of the enzyme. In both cases, the product is 5-
hydroxy-tryptophan which is then almost immediately converted into the 
neurotransmitter 5-HT via decarboxylation by a common enzyme, the aromatic 
amino acid decarboxylase (AADC). The AADC step is much faster than the TPH 
step, and therefore not rate-limiting. For an overview of tryptophan metabolism 
within the brain see Cooper et al. (2003). 
In the brain, 5-HT is utilized in many ways, not all yet fully understood. It is 
known that it plays an important role in the regulation of basic homeostasis 
including body temperature and sleep (Sallanon et al., 1982; Goodrich et al., 
1989; Rausch et al., 2003), emotions such as anger, aggression or mood in 
general (Van Praag, 1994; Schwartz et al., 1999; Giegling et al., 2006), and 
nutritional and reproductive functions like appetite, sexuality and arousal (Feist 
and Galster, 1974; Curzon, 1990; Menani et al., 2000; Popova and 
Amstislavskaya, 2002). Its postsynaptic effects can be inhibitory or excitatory, 
depending on the cell type and the receptor type that it interacts with. To date, 
about 15 genes encoding functional 5-HT receptors have been identified in the 
mammalian brain. With the exception of 5-HT3 receptors - which are ionotropic 
receptors - all others are metabotropic G-protein-coupled receptors (GPCRs) 
(Peroutka, 1992; Millan et al., 2008). Post-genomic modifications, such as 
alternative splicing or mRNA editing further broaden the range of 5-HT receptor 
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types. There are at least seven sub-classes of 5-HT receptors. 5-HT1 and 5-HT2 
were the first neuronal 5-HT receptors identified, with 5-HT1 being mainly 
inhibitory, whereas 5-HT2 rather exerts excitatory effects (Murphy et al., 1998; 
Barnes and Sharp, 1999). 5-HT1A receptors are autoreceptors that play a very 
important role in the immediate feedback / auto-regulation of 5-HT neurons, 
however, they are also found in postsynaptic membranes (Hjorth et al., 1996; 
Dos Santos et al., 2008). In contrast to classic neurotransmitter receptors, 5-HT 
receptors are rather localized around synapses (pre- or post-synaptically), but 
rarely within the synaptic cleft. The exact functions and intracellular signaling 
pathways of 5-HT-GPCR-interacting proteins are not yet fully understood, but 
may include fine-tuning of signaling, trafficking to or from the membrane, and 
desensitization.  
 Reuptake of 5-HT into neurons (and probably into glia cells) occurs by 
means of the serotonin transporter (SERT), a high-affinity monoamine 
transporter. This also serves as a major termination mechanism for the actions of 
5-HT. SERT mRNA is almost exclusively expressed in cell bodies of the DRN 
and the median raphe nuclei, but SERT protein can be transported to distant 5-
HT nerve terminals where it serves as a bi-directional plasma membrane carrier, 
depending on the extra-intracellular concentration gradient of 5-HT. Selective 5-
HT-reuptake inhibitors (SSRIs) such as Prozac® are a major group of 







Figure 1. Schematic illustration of serotonin (5-HT) synthesis. Tryptophan-
hydroxylase (TPH) is the rate-limiting (slow) enzyme during 5-HT production, 
catalyzing the hydroxylation of tryptophan with the help of the cofactor Fe2+ and 
the co-substrates O2 and tetrahydrobiopterin (BH4). Aromatic amino acid 
decarboxylase (AADC) then rapidly decarboxylates the resulting 5-
hydroxytryptophan to yield 5-HT. Figure from Walther and Bader (2003). 
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The cytosolic breakdown of 5-HT happens via deamination by monoamine 
oxidase (MAO). MAO is a target for another powerful class of antidepressants, 
the monoamine oxidase inhibitors (MAOIs). In the pineal gland, 5-HT is 
metabolized to melatonin by 5-hydroxyindole-O-methyltransferase. For the 
development of antidepressant treatments (such as tryptophan supplementation), 
it is important to recognize, however, that only about 1% of the body’s tryptophan 
gets metabolized along the 5-HT pathway. The other 99% are metabolized 
differently, along the kynurenine pathway. The strength of the kynurenin pathway 
in one individual compared to another might therefore be an important factor 
influencing the availablity of the serotonin precursor tryptophan (Schmitz et al., 
1974).  
 
B. THE DORSAL RAPHE NUCLEI – MAIN BRAIN SITE OF 5-HT SYNTHESIS 
The main brain site for 5-HT synthesis are the neurons of the raphe nuclei, 
and within those the dorsal raphe nuclei (DRN). The DRN are grouped into 
rostro-caudally distinct subpopulations. 5-HT neurons of the rostral DRN 
innervate forebrain areas thought to be involved in motivational behaviors (Fig. 
2), such as the frontal cortex, the caudate, putamen and substantia nigra, 
whereas 5-HT cells of the caudal DRN rather project towards limbic structures, 
such as the hippocampus, the entorhinal cortex and the lateral septum (Abrams 
et al., 2004). Collateral 5-HT projections from the mid DRN branch out to control 
functionally related targets and circuitries involved into autonomic control of 
anxiety and fear (Lowry, 2002; Lowry et al., 2005), such as the paraventricular 
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nucleus (PVN) of the hypothalamus and the central nucleus of the amygdala 
(CeA). This topography suggests a potentially regulatory role in emotion for all, 
and perhaps a unique functional property and behavioral implication for each of 
the 5-HT subpopulations in the DRN. 
 
C. THE 5-HT HYPOTHESIS OF DEPRESSION 
Dysfunction of 5-HT neurotransmission is the leading hypothesis 
regarding the pathophysiology of MDD (Arango et al., 2002; Mann, 2003; Lesch, 
2004) and other neuropsychiatric disorders such as schizophrenia (Veenstra-
VanderWeele et al. 2000), autism (Veenstra-VanderWeele & Cook 2004), 
aggression, suicidal behavior (Arango et al. 2003) and attention deficit disorder 
(Gainetdinov et al. 1999; Quist & Kennedy 2001). About one of five Americans 
suffers from an episode of major depressive disorder MDD during life (Kessler et 
al., 1994; Varghese and Brown, 2001; Bloom, 2004), and the prevalence for 
depression is twice as high in women than it is in men (Earls, 1987; Nolen-
Hoeksema, 1987). Currently, the “receptor-theory of depression” has replaced 
the earlier “monoamine theory of depression”. Most current antidepressants 
target the brain 5-HT system indirectly by inhibiting either the reuptake-receptor 
SERT or the 5-HT metabolizing enzyme MAO (Feldstein et al., 1965; Schmauss 
et al., 1988; Baker et al., 1992), or by binding to 5-HT receptors on target 
neurons (Cryan and Leonard, 2000; Berrocoso and Mico, 2008; Navines et al., 
2008). However, some antidepressants take several weeks to show the desired 
treatment effect (Frazer and Benmansour, 2002). One interpretation of this is that 
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more complicated post-synaptic changes, such as receptor expression levels in 
the target cells and of autoreceptors, are required before the drug is effective. 
Over the last years, more and more attention has been drawn toTPH2 itself 
(Walther et al., 2003; Zhang et al., 2004), which is greatly associated with 
neuropsychotic disorders (Zill et al., 2004; Zhang et al., 2005; Bach-Mizrachi et 
al., 2006; Harvey et al., 2007; Maron et al., 2007), and provides a direct target for 
control of brain 5-HT synthesis.  
       
 
 
Figure 2. Schematic illustration of 5-HT projections from the dorsal raphe nuclei 
in the human brain. Important forebrain target areas include the thalamus (Th), 
striatum (str), the septum (Sep), the hypothalamus (Hyp), the hipocampus (Hip) 
and the amygdala (Am). Other axons innervate the mesencephalic substantia 
nigra and the cerebellum, or are located within the spinal cord, innervating 
targets of the pripheral nervous system. Figure modified from 
http://abdellab.sunderland.ac.uk. 
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THE NEURONAL TRYPTOPHAN-HYDROXYLASE: DISCOVERY & 
DISORDERS 
TPH2 (Fig. 3) was recently discovered to be the neuronal-specific version 
of TPH (Walther and Bader, 2003; Zhang et al., 2004). Previous studies either 
did not discriminate between TPH1 and TPH2 or solely measured TPH1, the 
gene product that controls 5-HT synthesis in peripheral tissues and in the pineal 
gland, but shows a very weak expression in the DRN (Malek et al., 2005). TPH2 
activity requires not only substrate, but also O2 and BH4 (Fig. 1), for building the 
hydroxy-group. Soluble TPH2 is rather found in the pericaryal cytoplasm, 
whereas particulate TPH2 is more likely to be found in association with 5-HT 
synapses. Interestingly, TPH2 is only about 25-50% saturated with its substrate 
tryptophan under basal conditions (Hofto et al., 2008; Windahl et al., 2008). 
Tryptophan supplementation can thus hardly exhaust the enzyme’s capacity. The 
activity of the enzyme can be increased by phosphorylation through protein 
kinase A, by Ca2+-phospholipids and also by partial proteolysis (Winge et al., 
2008). The drug p-chlorophenylalanine binds competitively and irreversibly to the 
enzyme, and can be used in experiments as a strong, long-term (weeks) inhibitor 
of 5-HTP synthesis (Jequier et al., 1967; Alexander et al., 1980; Petkov et al., 
1995; Boot et al., 2002). 
By now, various studies have linked defective TPH2 expression to 
emotional disorders, especially to MDD and suicide (Zill et al., 2004). For 
instance, Zhang et al. (2005) identified a single nucleotide polymorphism (SNP) 
in the TPH2 coding region in about 13% of a group of patients suffering from mild 
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anxiety to severe unipolar depression. When human TPH2 with the same SNP 
(replacement of the highly conserved Arg441) is expressed in cell culture,  the 
same mutation causes an 80% reduction of 5-HT synthesis. Other studies 
revealed TPH2 SNPs in members of a French Canadian family with bipolar 
disease (Harvey et al., 2007), and among women with panic disorder (Maron et 
al., 2007). Paradoxically, TPH2 expression in the DRN of drug-free suicide 
victims was found to be 33% higher than in age-matched healthy controls (Bach-
Mizrachi et al., 2006). Yet, earlier studies reported less 5-HT and less of its 
metabolite, 5-hydroxyindoleacetic acid, in the midbrain of suicide victims and in 
the CSF of suicide attempters (Mann et al., 1989; Placidi et al., 2001). This 
logical discrepancy could be explained by a compensatory elevation of TPH2 
expression to regain 5-HT homeostasis in the brain, or possibly by a pathologic 
variation in the TPH2 gene as described above. All of the described genetic or 
functional studies (De Luca et al., 2005; Shink et al., 2005), however, suggest a 
link between chronically altered TPH2 expression and psychotic disorders.  
 
SEX DIFFERENCES IN MOOD DISORDERS   
Depressive, stress-related and anxiety disorders are twice as common in 
women as among men (Earls, 1987; Angold and Worthman, 1993; Weissman et 
al., 1993; Kornstein et al., 1995). Women also tend to respond differently to 
antidepressant medications than men (Kornstein, 1997; Gorman, 2006; 
Grigoriadis and Robinson, 2007), indicating that the cause and mechanism of 
mood disorders may be very different from males. In fact, various animal models 
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Figure 3. Overview of peripheral TPH1 versus brain-specific TPH2 functions. 
Although both enzymes catalyze the rate-limiting step for 5-HT synthesis, their 
role in physiology and various pathologies is very distinct. Top: in situ 
hybridization pictures of TPH1 mRNA expression in the pineal gland (left) and 
TPH2 mRNA expression in the DRN (right) of Sprague-Dawley rats. Bottom: 
Schematic representation of the peripheral versus central duality of the 5-HT 
system. Modified after Patel et al. (2004) and Walther and Bader (2003). 
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for affective disorders suggest profound sex differences in regulation of 
emotionality (Steenbergen et al., 1990; Caldarone et al., 2003; Toufexis, 2007) 
and in stress-induced performance deficits (Shors and Leuner, 2003; Shansky et 
al., 2006). In male rats, for instance, the exposure to an inescapable stressor 
greatly facilitates learning. In contrast, female rats respond to the same 
environmental event in the exact opposite way, and as a result are severely 
impaired in their ability to perform (Shors et al., 1998; Wood and Shors, 1998; 
Wood et al., 2001). Among all ovarian steroids, changing estrogen levels are 
thought to have the greatest effect on mood. Postpartum depression, as well as 
premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD) and 
menopause depression are all associated with a sudden drop in circulating 
estrogen (Rubinow, 1992; Halbreich et al., 1995; Buckwalter et al., 2001). 
Regrettably, exactly these steroidal fluctuations and changing baselines in 
females, have led to a reluctance towards studying the etiology of female 
depression, and to the common misassumption that the female neurobiology of 
depression is simply an extension of that observed in males. Hence, the female 
prevalence for depressive disorders and their different response to 
antidepressant treatment indicate an essential role of ERs in the regulation of 






ESTROGEN RECEPTORS: STRUCTURE & FUNCTION 
Estradiol has been reported to affect anxiety-related behaviors, yet a 
careful review of the literature shows that it can have both anxiogenic and 
anxiolytic effects. This initial contradiction may be explained by the functional 
difference between the two types of ER, ERalpha and ERbeta. ERalpha-selective 
agonists, such as propylpyrazoletriol (PPT, Stauffer et al. (2000)), are anxiogenic 
and increase the response of the hypothalamo-pituitary-adrenal (HPA) axis to a 
stressor, whereas ERbeta agonists (Meyers et al., 2001) like DPN  (Fig. 4 and 
Table 1) attenuate anxiety- and despair-like behaviors and decrease the HPA 
stress response (Walf et al., 2004; Lund et al., 2005; Walf and Frye, 2005). In the 
forced swim test, DPN treatment could even dampen depressive-like behavior of 
flinders sensitive rats (Osterlund et al., 1999), a strain selectively bred for 








Figure 4. Chemical structure of the selective ERbeta agonist diarylpropionitrile 
(DPN). DPN binds to ERbeta with a 70- to 80-fold higher affinity than to ERalpha 




 Fig. 5 depicts the two different ER proteins, ERalpha and ERbeta, each a 
product of separate genes, and each having several isoforms that are created by 
posttranscriptional modifications such as alternative splicing (Chu and Fuller, 
1997; Petersen et al., 1998; Price et al., 2000; Price et al., 2001; Chung et al., 
2007). The exon structures of recently discovered splice variants of ERbeta are 
shown as well in Fig. 5. ERs belong to a family of steroid hormone receptors that 
are ligand-activated transcription factors, all members of the “nuclear receptor 
superfamily”. Steroid hormones such as estradiol are lipophilic allowing for free 
passage through membranes. Thus, estradiol and steroid compounds can cross 
the plasma membrane as well as the nuclear membrane. ERs can be cytosolic or 
nuclear. Ligand binding induces conformational changes in the ER that may first 
promote the transport of the complex through pores of the nuclear membrane, 
and then lead to receptor-dimerization, receptor–DNA interaction at an estrogen 
response element (ERE), recruitment of coregulators and other transcription 
factors, and finally – after notable remodeling of the chromatin at the DNA 
binding site - the formation of the pre-initiation complex that is necessary for 
exposing the promoter-sequence of the gene of interest and preparing the gene 
for transcription (Migliaccio and Marino, 2003; O'Lone et al., 2004; Marino et al., 
2006). However, ERs not only regulate gene expression by binding to EREs, but 
also through protein–protein interactions with other transcription factors and 
coregulators (Tremblay and Giguere, 2001; Kang et al., 2002; Dutertre and 
Smith, 2003; Loven et al., 2004; Koide et al., 2007; Suzuki et al., 2007; Bovet et 
al., 2008; Ruegg et al., 2008). For instance, the nuclear receptors ERbeta1δ3 
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and ERbeta2δ3, two variants with a deletion of exon 3 coding for the DBD, 
colocalize with coactivator proteins of ER (cotransfected GFP-GRIP1 and 
endogenous CBP) in the presence of agonists (Price et al., 2001).  
Besides classic genomic mechanisms ERs can also act via rapid, non-
genomic (cytosolic) actions (Stirone et al., 2005; Mhyre and Dorsa, 2006). A 
prominent example is the membrane-anchored estrogen receptor GPR30 
(Revankar et al., 2005). Another splice variant of ERbeta lacks the fourth exon 
(δ4), which codes for the nuclear translocation signal. ERbeta1δ4 resides mainly 
in the cytosol, and does not seem to bind estrogen (Price et al., 2000). While the 
cytosolic location of ERbeta1δ4 may suggest rapid, non-genomic actions of the 
splice variant, little is yet known about its actual purpose. 
ERalpha and ERbeta share an almost identical (96%) DNA-binding 
domain (DBD) and bind to the same ERE (Kuiper et al., 1996). Although the 
ligand-binding domains (LBDs) are less homologous, the splice variant ERbeta1 
(historically the first ERbeta to be identified) binds estradiol with almost the same 
affinity as does ERalpha (Kuiper and Gustafsson, 1997). The novel splice variant 
ERbeta2 (Chu and Fuller, 1997; Chung et al., 2007), carries an 18-amino acid 
insert between the fifth and the sixth exon within the LBD. This causes ERbeta2 
to have a comparably low affinity for estradiol (Table 1). For both receptor types, 
ERalpha and ERbeta, synthetic ligands that can discriminate between the two 
types have been discovered, each displaying selective affinities for either ER, 
such as the ERalpha agonist PPT, or the ERbeta-specific agonist DPN (Table 1, 
Fig. 4). Natural discriminatory ligands, such as the ERbeta-favoring isoflavone, 
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Genistein (Table 1), had to be considered during the design of my experiments. 






Figure 5. Schematic representation of the relative homology between ERalpha 
(ERα) and ERbeta (ERβ) protein (top panel) and ERβ splice variant exon 
structure (lower panel). Deletions are indicated by a single line, and insertions 
are indicated by a shaded box. DBD=DNA-binding domain, LBD=ligand-binding 





Binding affinities of estradiol and selected compounds for ERalpha and 













Top: Binding affinities (Ki) of estradiol (E) and selective natural (Genistein) or 
artificial (DPN, PPT, Diethylstilbestrol, Moxestrol, 4-OH-Tamoxifen) ligands for 
ERalpha and ERbeta (top). Bottom: Dissociation constant (Kd), association half-
life and dissociation half-life (T1/2) of [
3H]-estradiol for ERalpha and selected 
ERbeta isoforms. ND=not determined. Tables obtained from Weiser et al. (2008).  
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LOCALISATION & FUNCTION OF ESTROGEN RECEPTOR BETA IN THE 
BRAIN 
Although ERalpha and ERbeta (also referred to as ERbeta1) both bind 
estradiol with about the same affinity, and bind to the same response element in 
DNA (Kuiper et al., 1996), they differ significantly in their neuroendocrine and 
behavioral function. ERalpha is vital for the control of reproduction in the brain 
and body (Ogawa et al., 1998; Hewitt and Korach, 2003), whereas studies of four 
different null mice mutants (βERKO) (either neo cassette insertions in the DNA-
binding domain or stop codon inserts throughout the gene) indicate that ERbeta 
is not required for immediate reproductive functions or sexual behavior (Ogawa 
et al., 1999; Couse et al., 2000; Nomura et al., 2006). In contrast to that, both 
sexes of a new βERKO mouse strain without any transcription past exon 2 (Antal 
et al., 2008) are sterile. To date, studies agree that brain ERbeta functions as a 
regulator of emotion-related behavior (Walf et al., 2008b), anxiety and stress 
responses (Krezel et al., 2001; Imwalle et al., 2005; Lund et al., 2005; Rocha et 
al., 2005; Toufexis et al., 2007; Walf and Frye, 2007a), and possibly of the 
negative feedback control of anterior pituitary luteinizing hormone (Dorling et al., 
2003). ERbeta has a similar binding affinity for estradiol as ERalpha (Kuiper et 
al., 1996), but posttranscriptional modifications of ERbeta, especially the novel 
splice variant ERbeta2 (Fig. 5), result in proteins that bind estradiol with a lower 
affinity. Such a dual receptor system could indicate adaptive changes in 
respective cells that would extend the range of sensitivity to higher 
concentrations of circulating estrogen (Petersen et al., 1998; Chung et al., 2007), 
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similar to the dual receptor system proposed for mineralocortocoid and 
glucocorticoid receptors (Reul and de Kloet, 1985). 
Ovarian hormones, primarily estrogen, have been shown to modulate 5-
HT function (Bethea et al., 1998; Joffe and Cohen, 1998; McEwen and Alves, 
1999). However, the limited expression of ERalpha in the raphe puzzled 
researchers until ERbeta was discovered and localized in the DRN of ERalpha-
knock-out (αERKO) mice (Shughrue et al., 1997a). Since then, ERbeta mRNA 
and / or protein have been repeatedly identified in the raphe nuclei of both sexes 
in mice (Mitra et al., 2003; Nomura et al., 2003; Vanderhorst et al., 2005) and 
primates (Gundlah et al., 2000; Gundlah et al., 2001), while ERbeta expression in 
the human DRN remains to be investigated. In guinea pigs, ERbeta, but not 
ERalpha is expressed in the raphe nuclei (Lu et al., 1999). The nature of ERs in 
the rat DRN is controversial as Lu et al. (2001) and Nomura et al. (2005) found 
that 5-HT neurons in the female rat DRN predominantly contain ERbeta, not 
ERalpha, but Sheng et al. (2004) did not find significant immunoreactivity for 
either ER in the rat DRN. Nonetheless, the qualitative variance between the 
employed anti-ERbeta antibody types and batches and the discovery of different 
splice variants raise the question whether the antibodies used may have failed to 
detect specific ERbeta variants. ERbeta1 is the original ERbeta; ERbeta2 is a 
splice variant containing an 18 amino acid insert in the ligand-binding domain; 
and deletion variants like ERbeta1δ3, ERbeta2δ3 and ERbeta1δ4 either lack the 
third or the fourth exon (Fig. 5). Since most ERbeta antibodies used in previous 
studies were created against the carboxy(C)-terminus of ERbeta, they should 
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automatically detect any splice variant, including ERbeta2. However, in my hands 
they only detected ERbeta in the far caudal DRN of female OVX rats, and in 
control regions like the cerebellum, but not in the rostral or mid DRN, where 
Chung et al. (2007) reported intense immunoreactivity of the novel splice variant 
ERbeta2. On one side of the argument, ERbeta was found to be expressed in the 
DRN of many other species, including mice, and is thus likely to be present in the 
raphe nuclei of rats as well. On the other side, a lot of studies show species 
differences in the expression pattern of ERs and other proteins (Young et al., 
1995; Gundlah et al., 2000; Sheng et al., 2004; Warembourg and Leroy, 2004). 
Therefore, it remains to be determined if the failure to detect ERbeta in certain 
immunocytochemical (ICC) studies is due to true species-dependent variations, 
or to a regionally modified epitope in the C-terminus.  
 
ESTROGEN RECEPTOR-MEDIATED GENE REGULATION IN 5-HT NEURONS 
An ERbeta-selective mechanism is proposed for many of the numerous 
estrogen-serotonin interactions on mood and cognition (for review see Amin et al. 
(2005)). For example, ERalpha is found in non-5HT neurons of the rat DRN, 
where estrogen regulates expression of progestin receptors but not of TPH 
(Alves et al., 1998). However, the αERKO mouse also shows estrogen-induction 
of progestin receptors in the DRN, implying that other ERs, for example ERbeta, 
are involved (Alves et al., 1998). In the cynomolgus monkey, phytoestrogens 
from soy, which are mostly selective for ERbeta, improve mood and enhance 5-
HT transmission in the DRN (Shively et al., 2003). Also, Nomura et al. (2005) 
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found that βERKO mice express significantly less TPH mRNA than wild type 
(WT) controls, whereas the synthesis of the enzyme was not altered in αERKO 
mice. A behavioral study reporting higher anxiety in βERKO mice compared to 
WT, additionally showed a reduced 5-HT content in the DRN of null mice 
(Imwalle et al., 2005). Most importantly, estradiol could be shown to selectively 
increase TPH2 expression in subregions of the DRN that are associated with 
attenuated anxiety (Hiroi et al., 2006). 
One of my own pilot studies also indicated that ERbeta could regulate 
gene expression in TPH2 neurons. Chronic systemic treatment of female OVX 
rats revealed that ERalpha activation by PTT (1mg/kg, s.c.) increases, but 
selective ERbeta activation via DPN (2mg/kg, s.c.) decreases the number of c-
Fos-immunoreactive TPH2 neurons within the dorsal mid DRN after exposure to 
forced swim stress (Fig. 6). The dorsal-mid DRN is of particular relevance for 
regulation of autonomic emotional responses, because collateral 5-HT 
projections from exactly this DRN subregion branch out to simultaneously 
innervate functionally related emotionality-regulating targets, such as the PVN 
and the CeA (Lowry, 2002; Lowry et al., 2005). The opposing effects of PPT 
versus DPN generally support the hypothesis that the two types of ERs (alpha 
and beta) hold functionally distinct roles that may include opposing regulation of 
5-HT-neuronal stress-reactivity. Consistent with the indication of ERbeta2 in the 
DRN of female rats by Chung et al. (2007), my recent dual-ICC results 
furthermore suggest a predominant expression of ERbeta2 in TPH2 neurons and 
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Figure 6. Seven days of daily subcutane treatment with DPN decreases acute c-
Fos stress-reactivity of TPH2 neurons. PPT has the opposite effect. Female OVX 
rats were stressed for 5 min by forced swimming, and sacrificed via intracardial 
perfusion with 4% paraformaldehyde 1 h after termination of the stressor. 
Numbers in parenthesis indicate group size. p* < 0.05, p** < 0.01 vs. Veh 





Figure 7. Photomicrographs showing dual-label ICC: ERbeta2-positive TPH2 
neurons and ERalpha-negative TPH2 cells in the female rat DRN. The nuclear 
steroid receptors are labeled in black / purple, the cytoplasmatic TPH2 protein is 
visualized in brown. Note that nuclei other than within TPH2 neurons are also 
positive for ERbeta2, and that ERalpha-positive cells are located adjacent to the 
TPH2 neurons depicted. The TPH2 antibody was kindly provided by Drs. Kuhn 
and Sakowski. For methodological details see Sakowski et al. (2006). ERbeta2-
ICC was performed after a protocol established by Chung et al. (2007). 
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SUMMARY & HYPOTHESIS 
The evidence provided indicates that more detailed examination of 
ERbeta’s involvement in the regulation of 5-HT-neuronal gene expression is 
required, especially with respect to the vast prevalence of depressive disorders 
and their impeding effect on the quality of life. The identification of disrupted 
TPH2 functionality or homeostasis in patients with mood disorders ranging from 
mild to major emotional disorders (Zill et al., 2004; Zhang et al., 2005; Harvey et 
al., 2007; Maron et al., 2007) and in suicide victims (Bach-Mizrachi et al., 2006) 
first proposed the involvement of this 5-HT-producing enzyme in the regulation of 
emotional health. It also bore the question of what may control the expression of 
TPH2. Estrogen’s interactions with the serotonergic system (Amin et al., 2005; 
Hiroi et al., 2006), ERbeta’s anxiolytic functions (for review see Weiser et al. 
(2008)), and the presence of the beta- but not the alpha type of ER in 5-HT DRN-
neurons of various species (Shughrue et al., 1997a) then suggested a role for 
ERbeta in 5-HT-neuronal regulation. The phenotype of reduced TPH expression 
and lowered 5-HT content in the DRN of βERKO mice (Imwalle et al., 2005; 
Nomura et al., 2005) and the finding that ERbeta-selective agonists can alter 5-
HT neurotransmission and gene expression in TPH2 neurons (Shively et al. 
2003; our preliminary data) further strengthened my hypothesis that local ERbeta 
activation in 5-HT neurons of the DRN directly regulates TPH2 expression and 
decreases anxiety- and depressive-like behaviors. This hypothesis was to be 
tested via systemic delivery of ERbeta agonist in the first experiment, and local, 




Estrogen receptor beta acts locally to regulate the expression of 
tryptophan-hydroxylase 2 mRNA within serotonergic neurons  
of the rat dorsal raphe nuclei 
ABSTRACT 
Affective disorders are often associated with a disruption of the brain 
serotonin (5-HT) system and are twice as common in women compared to men. 
The median and dorsal raphe nuclei constitute the main source of 5-HT in the 
brain, and contain 5-HT cells that send projections to innervate important 
forebrain and limbic areas. Further, all 5-HT neurons of the raphe nuclei express 
tryptophan hydroxylase-2 (TPH2), the brain specific, rate-limiting enzyme for 5-
HT synthesis. Previously, it was shown that ERbeta agonists attenuate anxiety- 
and despair-like behaviors in rodent models. Here, we tested the hypothesis that 
ERbeta is involved in the regulation of 5-HT gene expression in neurons of the 
dorsal raphe nuclei (DRN) by examining the effects of systemic versus local 
application of the selective ERbeta agonist diarylpropionitrile (DPN) on TPH2 
expression within the DRN of female rats.  
For the first experiment, young adult, ovariectomized (OVX) female rats 
were injected s.c. with DPN (2mg/kg) or vehicle (27% hydroxypropyl-beta-
cyclodextrin) once daily for 8 days. Animals were tested for anxiety-like behavior 
in the open field (OF) and on the elevated plus maze (EPM) after 6 and 7 days of 
treatment, respectively. The results confirmed the anxiolytic nature of ERbeta, as 
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DPN-treated rats displayed more rears at the wall of the OF, and spent more 
time in the open arms of the EPM while entering open arms more frequently and 
with a shorter initial latency than controls. The following morning, all rats were 
killed 4 hours after the last injection under non-stress conditions. In situ 
hybridization revealed that systemic DPN-treatment significantly elevated basal 
TPH2 mRNA expression in the caudal and mid-dorsal DRN. 
In a second experiment, young adult, OVX female rats were implanted 
bilaterally with wax pellets flanking the DRN. Pellets contained either 17-beta-
estradiol (E, 0.5 µM), DPN (0.5 µM) or no hormone. Unoperated individuals 
served as additional controls. DPN- and E-treated rats displayed a more active 
stress-coping behavior in the forced-swim test (FST), as they struggled longer 
than controls. However, no significant differences in anxiety-like behaviors were 
found between any of the treatment groups in the OF or on the EPM. TPH2 
mRNA in the DRN was measured using in situ hybridization. DPN significantly 
enhanced the TPH2 mRNA expression in the mid-dorsal and in the caudal DRN, 
compared to both control groups. Similarly, animals of the E-treated group also 
expressed more TPH2 mRNA than controls in the mid-dorsal DRN. 
Taken together, these data indicate that local activation of ERbeta 
neurons in the DRN is sufficient to decrease despair-like behavior, whereas 
action of ERbeta in other brain regions is necessary to alter anxiety-like 
behaviors. These results suggest an important role of ERbeta for regulating 
cellular events in the DRN. ERbeta acts locally to control TPH2 mRNA levels and 
consequently 5-HT synthesis in the certain subregions of the rat DRN.      
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INTRODUCTION 
 Major depressive disorder (MDD) affects about 17% of Americans 
(Kessler et al., 1994; Williams et al., 2007), and is unquestionably a complex, 
heterogeneous disease (Winokur, 1997; Ellard, 2001; Weissman, 2002). A 
deficiency in serotonergic (5-HT) neurotransmission, however, is the leading 
hypothesis regarding the development and pathophysiology of this disease 
(Owens and Nemeroff, 1994; Arango et al., 2002; Perlis et al., 2002; Lesch, 
2004). Furthermore, the incidence, duration, severity and rate of reoccurrence of 
depressive disorders are twice a high in women compared to men (Earls, 1987; 
Angold and Worthman, 1993; Weissman et al., 1993; Kornstein et al., 1995). 
Women also tend to respond differently than men to common antidepressant 
treatments, such as selective serotonin-reuptake inhibitors (SSRIs) (Kornstein, 
1997; Gorman, 2006). This ratio together with numerous animal models reporting 
sex differences in the regulation of emotionality (Steenbergen et al., 1990; 
Caldarone et al., 2003; Shors and Leuner, 2003; Toufexis, 2007) and an 
interaction between estrogen and the serotonergic system (for review see (Amin 
et al., 2005)) suggest that estrogen receptor (ER)-mediated mechanisms may 
underlie the etiology of MDD.  
In animal models, estradiol is capable to exert both, anxiolytic, but also 
anxiogenic effects, depending on the behavioral context (Koss et al., 2004; Hiroi 
and Neumaier, 2006). This ambiguity may be explained by the two different 
receptor systems, ERalpha and ERbeta. While ERalpha-selective agonists are 
anxiogenic, ERbeta-specific agonists, such as diarylpropionitrile (DPN), have 
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been shown to exert potent anti-anxiety effects (Walf et al., 2004; Lund et al., 
2005; Maier and Watkins, 2005; Walf and Frye, 2005). The endogenous ligand 
estradiol binds to and activates both receptor types with about the same affinity 
(Kuiper et al., 1997). In flinders-sensitive rats, a rat strain selectively bred for 
depression, ERbeta agonists reduce the animals’ passive floating and immobility 
behavior (Overstreet et al., 2006) during the forced swim test (FST), a test 
established to assess despair-like behavior in rodents by measuring their active 
versus passive stress-coping strategies (Porsolt et al., 1977). Rats of the same 
animal model also display abnormal levels of 5-HT receptor transcripts for 5-
HT(2A) in the perirhinal cortex, piriform cortex, medial anterodorsal amygdala 
and in the hippocampus, a phenotype that is reversed by estrogen-treatment 
(Osterlund et al., 1999). Considering the importance of the 5-HT system for 
anxiety- and depressive disorders, we thus hypothized that local ERbeta 
activation regulates gene expression within 5-HT neurons, ultimately resulting in 
decreased anxiety- and despair-like behavior. 
The brainstem dorsal raphe nuclei (DRN) are the primary 5-HT system of 
the brain. Distinct DRN subdivisions give rise to axons that innervate most 
forebrain areas, including areas crucial for the regulation of emotion and stress-
coping behavior, such as the amygdala and the paraventricular nucleus of the 
hypothalamus (Imai et al., 1986; Petrov et al., 1992). Other subregions of the 
DRN send projections to motivational areas like the prefrontal cortex (Lowry, 
2002; Abrams et al., 2004), while axons from the caudal DRN target limbic 
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structures, such as the hippocampus, the entorhinal cortex and the septum 
(Kohler and Steinbusch, 1982).  
Within each 5-HT neuron, tryptophan-hydroxylase 2 (TPH2), the recently 
discovered, brain-specific version of the enzyme (Walther et al., 2003; Zhang et 
al., 2004), catalyses the rate-limiting step of 5-HT synthesis. Disruption or 
dysfunction of TPH2 itself is strongly correlated with affective disorders (Zill et al., 
2004; Zhang et al., 2005; Haghighi et al., 2008), and abnormal TPH2 expression 
may be responsible for much of the pathology described.  
The hypothesis that ERbeta-mediated actions may regulate the 
expression of TPH2 is supported by the robust expression of ERbeta within the 
DRN of mice (Shughrue et al., 1997a; Mitra et al., 2003; Nomura et al., 2005; 
Vanderhorst et al., 2005), primates (Gundlah et al., 2000; Gundlah et al., 2001) 
and guinea pigs (Lu et al., 1999), whereas ERalpha is only expressed to a 
miniscule extent in the DRN of most of these species. The nature of ERs in the 
rat DRN, however, remains controversial. In the female rat DRN, Lu et al. (2001) 
reported strong immunoreactivity for ERbeta1, the first ERbeta variant to be 
discovered (Green et al., 1986), and Chung et al. (2007) for ERbeta2 - a novel 
splice variant. In contrast, Sheng et al. (2004) did not detect any significant 
immunoreactivity for either ERbeta or ERalpha in female or male rat DRN.  
Some studies already demonstrated that ERbeta activation can regulate 
gene expression in the brainstem. First, Alves et al (2000) discovered estrogen-
mediated induction of progestin receptor expression in the DRN of ERalpha null 
mice (αERKO), suggesting a role for ERbeta. Later, ERbeta-selective 
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phytoestrogens were determined to improve mood and 5-HT neurotransmission 
in the cynomolgus monkey (Shively et al., 2003). Subsequently, Nomura et al. 
(Nomura et al., 2005) found significantly less TPH mRNA expressed in the DRN 
of βERKO mice than in wild type. βERKO mice also displayed increased anxiety-
like behavior in conjunction with a lower 5-HT content in the DRN (Imwalle et al., 
2005). Recently, estrogen-treatment was demonstrated to increase TPH2 
expression especially in those DRN subregions that are associated with 
attenuated anxiety (Hiroi et al., 2006). 
The described findings all support the hypothesis that ERbeta activation in 
the DRN may be sufficient to alter behavioral parameters and TPH2 gene 
expression in the DRN. Therefore, we examined the effects of chronic systemic 
versus local delivery of ERbeta agonist DPN in female, ovariectomized (OVX) 
rats on anxiety- and despair-like behavior as well as on TPH2 mRNA expression 
in all subdivisions of the DRN. 
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MATERIAL & METHODS 
 
Animals 
All animal surgeries, behavioral tests and experimental protocols followed 
NIH and AAALAC guidelines and were approved by the Animal Care and Use 
Committee at Colorado State University. Young adult female Sprague-Dawley 
rats (200-250 g body weight, Charles River Laboratories, Wilmington, MA) were 
kept under standard laboratory conditions (12:12 h light-dark cycle, lights on at 
0600 h, 22 °C, 60 % humidity, and ad libitum access to water and food). All rats 
were fed a phytoestrogen-free chow diet (Harlan Laboratories, San Diego, CA) 
for the entire duration of the experiment starting one week before ovariectomy 
(OVX) to avoid uncontrollable phytoestrogen effects. Surgical procedures were 
performed under isoflurane- (for OVX) or ketamine-anaesthesia (93% ketamine, 
5% xylazine, 2% acepromazine; for stereotaxic wax pellet implantations). All 
animals were handled and their weight monitored every other day for the duration 
of both experiments. 
 
Experimental design and surgical procedures 
All rats underwent bilateral OVX through the dorsal approach one week 
after arrival, to remove circulating gonadal steroids, and to ensure a constant, 
high level of ERbeta expression within the brain (Suzuki and Handa, 2005). 
Chronic 8-day systemic or local, intracerebral treatment with ER ligands began 
one week after OVX. The animals’ weight was measured every other day during 
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the treatment period, and all animals were double housed with a partner of equal 
treatment throughout each experiment. 
 
Experiment 1:  Systemic DPN treatment 
Rats were injected s.c. with ERbeta agonist diarylpropionitrile (DPN, 
2mk/kg, n=8) or vehicle (27% hydroxypropyl-beta-cyclodextrin in PBS, n=8) once 
per day at 0600 h. DPN was synthesized de novo following an established 
protocol (Lund et al., 2005). While estrogen binds to both ERalpha and ERbeta 
with almost the same affinity,  the relative binding affinity of the selective agonist 
DPN is about 70 to 80-fold stronger for ERbeta than for ERalpha (Kuiper et al., 
1998; Meyers et al., 2001). On days 6, rats were tested for anxiety-like behavior 
in the open field (OF) and on day 7 on the elevated plus maze (EPM). All animals 
were killed by decapitation on day 8 under basal, non-stress conditions between 
1000 and 1200 h (4 h after the last DPN injection to avoid acute effects of steroid 
treatment). Their brains were removed, immediately fresh-frozen in dry-ice-
cooled methylbutane (-40° C) and stored at -80° C until sectioning.  
 
Experiment 2:  Local DPN treatment 
Three groups of rats were stereotaxically implanted bilaterally with wax 
pellets (each 2.0 mm long to target the ventro-dorsal extent of the DRN 
sufficiently) flanking the dorsal raphe. Stereotaxic coordinates were 8.0 mm 
posterior to bregma, ± 1.5 mm lateral of the skull’s midline, 5.5 mm deep; and 
pellets were lowered into the brain at a 7° angle. Each pellet contained either 0.5 
µM DPN (n=10), 0.5 µM 17-beta-estradiol (Sigma, St. Louis, MO; E, n=10) or 
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beeswax only (VWR International, Bristol, CT; vehicle control, n=10). To prepare 
the pellets for implantation, the tip of a sterile 22-gauge stainless steel outer 
cannula (Small Parts, Miami Lakes, FL) was packed with the respective 
compound, which was then lowered into the brain according to the stereotaxic 
coordinates mentioned above. A 28-gauge inner stylet was used to slowly expel 
the pellet from the outer cannula. After pellet implantation, the outer cannula was 
removed and the scalp sutured. At the time of the behavioral testing in the FST, 
the cranial incision site had healed completely on all individuals. Lund et al. 
(Lund et al., 2006) verified the diffusion of DPN and other steroids to be 
contained within a 0.5 mm radius around the pellet, ensuring that the compounds 
used in the present study successfully diffused into all rostro-caudal and medial-
to-lateral subregions of the DRN without damaging any tissue within the target 
nuclei. Another control group of OVX animals remained unoperated for 
comparison with behavioral and cellular parameters of operated animals. All 
animals were tested in the OF and on the EPM on days 5 and 6 of treatment. On 
day 7, rats were subjected to the forced-swim test (FST) to assess despair-like 
behavior. As in the first experiment, all animals were killed by decapitation on day 
8 between 1000 and 1200 h under basal, non-stress conditions, their brains 
removed, fresh-frozen and stored at -80° C until sectioning. 
 
Behavioral testing & evaluation 
All rats were tested in the open field (OF) and on the elevated plus maze 
(EPM) on two consecutive days for 5 min each, between 1000 and 1200 h. Both 
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the OF and the EPM are designed to assess anxiety-related behavior by creating 
a conflict situation between the rodent’s natural explorative drive and its innate 
fear of open, exposed areas (Pellow et al., 1985).  
The OF is an 80 x 80 cm open square box with 30 cm tall walls. 
Symmetrical lines drawn on the bottom of the box, divide the box floor into 
“protected” outer squares (adjacent to the walls) and “exposed” center squares. 
Light intensities were 65 lx in all squares facing the wall, and 80 lx in the center 
spare. At the beginning of the test, each animal was placed in the center of the 
OF. The following parameters were scored (Handa et al., 1993): locomotor 
activity (total of square line crossings), rears at walls, time spent in (exposed) 
center squares, time spent in (protected) outer squares, time spent grooming, 
number of fecal boli. Time spent in the center of the OF, and an increased 
number of rears, are both considered low-anxiety explorative behavior. More 
fecal boli and long grooming periods usually indicate a state of elevated anxiety 
or displacement-activity, respectively.  
The EPM consists of a plus-shaped platform at about 80 cm elevation with 
two opposing closed arms (arms about 80 cm long with 30-cm tall walls) and two 
opposing open arms (no walls). All four arms are connected via a 10 x 10 cm 
neutral zone in the middle of the maze. Light intensities were 25 lx in the closed, 
80 lx in the open, and about 60 lx in the neutral zone. Each rat was placed onto 
the mace facing one of the closed arms. The latency until first open arm entry, 
the time spent in the open and closed arms, the number of closed and open arm 
entries, the time spent grooming, and the number of fecal boli were recorded 
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(Handley and McBlane, 1993). The number of closed arm entries is generally 
used to describe overall locomotion and activity of the animal. The number of 
open arm entries and the time spent in the open (exposed) arms are evaluated 
as low-anxiety-like behavior, the time spent in the closed arms and an elevated 
number of fecal boli as high-anxiety-like behavior. Since grooming occurred in 
closed and for some animals in open arms, it was referred to as neutral (neither 
high- nor low-anxiety-like) behavior. 
All rats of the second experiment were also exposed to the forced swim 
test (FST) for 5 min on day 7 after intracerebral pellet implantation. The FST is 
based on a rationale for testing and interpreting despair-like behavior in rodents 
(Porsolt et al., 2001). We intended to distinguish between mere explorative 
versus timid behavior (EPM and OF) on the one hand, and active versus passive, 
depressed behavior (FST) on the other hand. In accomplishment of the latter, the 
FST applies a strong physical challenge for the evaluation of active versus 
passive stress coping behaviors (Keay and Bandler, 2001). All animals swam for 
5 min in tap water with a consistent temperature of 25 °C, and were removed and 
dried with a clean towel afterwards. The time paddling (normal stress-coping 
behavior: slow-pace front and hind leg movements to keep the nose over water), 
the time struggling (active stress-coping behavior: high-pace front leg paddling 
and strong hind leg strokes with the intension to escape the situation), the time 
spent floating (passive, despair-like stress-coping behavior: minimal leg 
movements, stiff, floating body posture) and the number of dives (active stress-
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coping, exit-seeking behavior) was recorded. After each behavioral test, animals 
were returned to their home cages and housed with the same partner as before.  
 
 RNA isolation & RT-PCR 
For the production of a riboprobe specific for tryptophan hydroxylase 2 
(TPH2) mRNA, fresh-frozen brains from three separate female OVX Sprague-
Dawley rats were cryocut (Leitz 1720 digital cryostat) at –12° C from bregma -6.5 
mm to – 9.5 mm into 300-µm thick coronal brainstem sections. DRN tissue was 
collected from these sections via the micropunch sampling procedure (Handa et 
al., 1987; Price et al., 2000), using a blunted needle with a 1000-µm diameter 
and a dry-ice-cooled stage. The micropunched tissue samples were immediately 
transferred and pooled into nuclease-free microcentrifuge tubes with 250 µl GIT 
buffer (4 M guanidine isothiocyanate, 25 mM sodium citrate at pH 7.0, 0.5% 
sarcosyl, and 0.1 M beta-mercaptoethanol). Total RNA isolation from 
microdissected brain tissue was conducted on ice according to the protocol 
established by Chomczynski and Sacchi (1987). First, the tissue-buffer mixture 
was homogenized mechanically. Subsequently, 25 µl of 2 M sodium actetate (pH 
4.0), 250 µl buffer-saturated phenol (pH 4.3) and 75 µl of chloroform–isoamyl 
alcohol at a 49:1 ratio were added. After vortexing, the reaction was allowed to sit 
on ice for 15 min, and was then spun at 14,000 g for 10 min to recover the 
aqueous phase. RNA was precipitated with ethanol, resuspended in GIT buffer, 
and precipitated a final time. RNA pellets were isolated in a last centrifugation 
step at 14,000 g, followed by two short wash steps with ice-cold 70% ethanol. 
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Total RNA was reconstituted in 20 µl RNAse-free water each and nucleic acid 
concentration determined at a spectrometer. 1 µg RNA was reverse transcribed 
with MMLV-RT (Invitrogen, Carlsbad, CA) using 1 µl oligo dT primers, dNTPs 
(100 mM each), 1st strand buffer (100 mM Tris–Cl–900 mM KCl–1 mM MgCl) 
and 2.5 mM DTT. The reaction was carried out at 37° C for 50 min, followed by 
heat-denaturation of the reverse transcriptase for 10 min at 95° C. The product, 
total cDNA from the DRN region, was stored at -20° C for later use. 
 
Design of the TPH2 riboprobe  
To generate a TPH2-specific plasmid DNA template for cRNA synthesis, a 
583 bp fragment of the TPH2 cDNA was amplified by RT-PCR (forward primer: 
5’-GGG GTG TTG TGT TTC GGG-3’, reverse primer: 5’-GTG GTG ATT AGG 
CAT TCC-3’). Several online BLASTs, researching the 583 bp TPH2 cDNA 
sequence in an NIH-supported database (http://blast.ncbi.nlm.nih.gov), did not 
return any other matching sequences besides the gene of interest. PCR 
conditions were: 45 s denaturation at 95° C, 45 s annealing at 55° C, and 45 s 
elongation at 72° C. After 35 cycles, a final 7-min elongation step at 72° C was 
added. The 50 µl PCR reaction volume contained 1.5 mM Mg2+, 0.2 mM dNTPs, 
0.2 µM forward and reverse primer, 50 ng template cDNA, and 1.0 unit Taq DNA 
polymerase (Eppendorf, Westbury, NY). The PCR product was gel-purified 
(Qiagen, Valencia, CA) and TA-subcloned into the linearized 4.0 kb TOPO-vector 
pCR®II (Invitrogen, Carlsbad, CA) via the vector-attached topoisomerase I. The 
plasmid was then transformed into chemically competent TOP10 bacterial cells 
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(Invitrogen) for vector-amplification and selection of successful clones (ampicillin 
resistance and “white”-selection due to loss of lacZ gene expression). Successful 
clones were verified using restriction enzymes cutting within the desired insert 
and subsequent gel-electroporesis, and via sequencing (Retrogen, San Diego, 
CA). Sequencing also revealed the orientation of the cDNA insert within the 
vector. Once the sequence had been confirmed, a plasmid MAXI-prep (Qiagen) 
was performed to yield sufficient amounts of cDNA template. Antisense and 
sense (control) TPH2 cRNAs were transcribed from the plasmid in the presence 
of [35S]-UTP, using either the restriction enzyme BlpI and T7 RNA-polymerase, or 
XbaI and Sp6 polymerase respectively. The specificity of the riboprobe was 
confirmed in two hybridisation test runs. The cRNA probe successfully detected 
TPH2 mRNA within the brainstem raphe nuclei, but did not hybridize within 
sections of the pineal gland where the peripheral isoform of the gene, TPH1, is 
expressed (Patel et al., 2004; Malek et al., 2005). The sense control probe did 
not hybridize with any specific areas in the brain. 
 
Tissue preparation & In situ-hybridization (ISH) 
 A Leitz 1720 digital cryostat (-20° C) was used to cut and thaw-mount 
series of coronal 16-µm brainstem sections beginning at bregma –6.5 mm to –9.5 
mm (Paxinos and Watson, 1998), covering the entire rostro-caudal extent of the 
DRN. Sections were thaw-mounted onto Superfrost plus slides (VWR Scientific, 
West Chester, PA), and stored at -80° C until assayed. For the ISH assay, tissue 
sections were thawed at room temperature, fixed within 10% paraformaldehyde, 
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acetylated with 0.25% acetic anhydride, dehydrated in a graded series of 
alcohols, and air-dried to prepare the tissue for the hybridization step. Sections 
were then incubated for 2 h in the pre-hybridization solution (50% formamide, 
0.60 M NaCl, 0.02 M Tris, 0.01 M EDTA, 10% dextran sulfate, 2 M Denhart’s 
solution, 50 mM dithiothreitol, 0.2% SDS, 100 mg/ml salmon testis DNA, 500 
mg/ml total yeast RNA, and 50 mg/ml yeast transfer RNA) and again dehydrated. 
In the following step, sections were incubated with the actual hybridization 
solution, containing all components of the pre-hybridization solution plus the 
radiolabeled cRNA at a concentration of 2 x 107 cpm/ml, in moisturized chambers 
at 60° C overnight. After hybridization, slides were rinsed in 2 x SSC. Remaining 
non-hybridized RNA was digested in a  30 mg/ml RNase A solution for 30 min at 
37° C. A final wash series in 0.1 x SSC preceded the final dehydration in graded 
alcohols.  
Hybridization was first validated by opposing slides to a 35S-sensitive 
Biomax MR film (Kodak, Rochester, NY) for 14 hours. Subsequently, 
hybridization was detected using photographic-emulsion-coated slide 
autoradiography. In a humidified dark room, all slides were slowly dipped twice 
into preheated (40° C) photographic emulsion (NTB-3; Kodak), air-dried, and 
stored at 4° C in the dark for 2 days. All slides were then developed using Kodak 
D-19 photographic developer, before counterstaining with cresyl violet. 
 
Validation of pellet implantation  
For single-cell identification and neuroanatomical validation of wax pellet 
placement, all sections were counterstained with 0.013% cresyl violet in 0.2 M 
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Walpole buffer (3 parts 0.2 M acetic acid and 2 parts 0.2 M sodium acetate) at 
pH 4.45. Sections were stained for 20 min, dehydrated in ascending alcohols, 
cleared in xylene, and mounted with Permount (Fisher Scientific, Pittsburg, PA). 
After evaluating each DRN series (12 sections per animal), using bright-field 
microscopy, the center location of each pellet was estimated and mapped in the 
corresponding coronal section in the rat brain atlas (Paxinos and Watson, 1998). 
Animals with pellets placed more than 0.5 mm away from the DRN in any 
direction were excluded from all data analysis. This criterion was defined 
empirically by Lund et al. (2006) who found the diffusion of [3H]-labelled E to be 
confined within a 0.5 mm area surrounding the wax pellet. Based on this 
parameter for steroid diffusion, one of the individuals of the vehicle-group (now 
n=9) was excluded for analysis. Every other bilateral pellet placement passed the 
neuroanatomical criterion. See Fig. 13 for details.  
 
Image analysis & Quantification of mRNA expression 
  All digital bright-field or dark-field images of cresyl-violet-counterstained,  
hybridized brain sections were captured by a Zeiss AxioCam HR camera on an 
Axioplan 2 microscope controlled by Axiovision, version 3.1, software. Three 
rostral, three mid and three caudal sections per animal were anatomically 
matched with the corresponding page in the rat brain atlas (Paxinos and Watson, 
1998) and used for further image analysis with the help of ImageJ  software 
(version 1.31, National Institute of Health, http://rsb.info.nih.gov). Matrices in 
shape of the brain regions of interest (see Fig. 11) were utilized to assess TPH2 
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mRNA expression within all subregions of the DRN via two different approaches. 
After subtraction of background activity (determined in an adjacent area devoid of 
silvergrain labelling), six (lateral mid DRN) or three values (dorso-rostral, ventro-
rostral, dorso-mid, ventro-mid, dorso-caudal, ventro-caudal) per animal were 
averaged for each subregion. In the first approach (from here on called “area-
analysis”), following inversion of the dark-field image, the area covered by black 
pixels was determined. Digital image inversion was background-corrected and 
standardized at the same inversion-threshold. The second approach (from here 
on called “intensity-analysis”) assessed single-cell intensity of mRNA expression 
by directly measuring the intensity of light reflected from the silvergrain-coverage 
of the cell of interest. Cells were picked randomly via a symmetrical grid 
overlaying the respective subregion. Only cells on grid crossings were analysed. 
Ultimately, the average intensity per cell and subregion was calculated.  
 
Statistical Analysis 
All data are expressed as the mean ± standard error of the mean (SEM). 
For studies with only two treatment groups,  the non-parametric Mann-Whitney-U 
test was used for pair wise data comparison. Results of all studies with more 
than two groups were analyzed by one-way ANOVA (factor treatment) followed 
by Tukey’s post hoc test where appropriate, using SPSS 12.0 for Windows 





The overall weight gain (day 8 minus day 1) during the two experiments is 
shown in Table 2. Neither systemic delivery of DPN nor central, site-specific 
administration into the DRN caused significant differences in weight gain, 
compared to vehicle controls. Similarly, local delivery of E into the DRN did not 
impair normal weight gain. All E-treated rats gained the same amount of weight 
as vehicle controls. 
Wax-pellet implantation per se did not affect the animals’ weight gain 
either, as it becomes obvious in the comparison with unoperated control rats 
(Table 2).     
 
Systemic delivery of DPN decreases anxiety-like behavior, but local DPN 
administration does not 
The animals’ anxiety-like behavior was tested in two different paradigms: 
the elevated plus maze (EPM), and the open field (OF). Both behavioral tests 
confirmed the anxiolytic effect of DPN when administered systemically (Fig. 8). 
On the EPM, DPN treatment caused the rats to enter the open arms sooner (p < 
0.01), more often (p < 0.05), and stay on the open arms longer (p < 0.05) than 
vehicle controls (Fig. 8 A). The number of entries into the closed arms did not 
differ between the two treatment groups, indicating that DPN did not increase the 
rats’ overall activity or locomotion behavior. None of the other parameters (time 
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grooming, time in closed arms, fecal boli) showed significant differences between 
any of the treatment groups.   
In the OF (Fig. 8 B), s.c. DPN-treated animals displayed more rears at the 
walls than their vehicle-treated counterparts (p < 0.01). The total number of 
square line crossings did not differ between the two treatment groups, suggesting 
that there was no overall effect on activity. The time spent grooming and the 
numbers of fecal boli were not significantly different between the treatment 
groups. 
Local, site-specific delivery of DPN or E did not alter any of the parameters 
measured in the EPM and the OF, compared to the vehicle group (Fig. 9, A and 
B). The animals from the unoperated control group did not differ from the vehicle 
control group in any of the behavioral tests (data not shown).   
 
Local delivery of both DPN or E enhances active stress-coping behavior  
Rats that were implanted with bilateral E- or DPN-pellets flanking the 
DRN, spent more time actively struggling in the water than did vehicle controls 
(Fig. 10; F3,32=4.628; p < 0.05). Accordingly, DPN-treated rats tended to spend 
less time passively floating than vehicle-treated rats. Local E-treatment also 
caused the rats to float more than animals of the DPN group (F3,32=3.489; p < 
0.05). Animals of all treatment groups paddled (neutral stress-coping behavior) 




Systemic DPN treatment increases TPH2 expression in the caudal and dorso-
mid DRN 
 To test the hypothesis that local, site-specific ERbeta activation in the 
DRN is sufficient to upregulate TPH2 mRNA expression, ISH was performed. 
Two different types of image analysis, measuring either the area positive for 
TPH2 expression (Fig. 11 B), or single-cell intensity of TPH2 expression (Fig. 11 
D), were applied.  
Results from area-analysis: Compared to vehicle-treated animals, daily 
s.c. administration of DPN significantly enhanced TPH2 mRNA levels in the 
dorso-mid (p < 0.05), the dorso- caudal (p < 0.05) and the ventro-caudal (p < 
0.05) DRN (Table 3 A). Accordingly, total TPH2 mRNA levels in the entire caudal 
DRN were significantly increased in the DPN group (p < 0.01; Fig. 11 A). 
Results from single-cell intensity-analysis: The intensity-based analysis of 
TPH2 revealed significant differences in the same subdivisions of the DRN as the 
area-analysis. Compared to vehicle-treated animals, systemic DPN-treatment 
significantly enhanced TPH2 mRNA levels in the dorso-mid (p < 0.01), the dorso- 
caudal (p < 0.01) and the ventro-caudal (p < 0.05) DRN (Table 3 B). Accordingly, 
total TPH2 mRNA levels in the entire caudal DRN were significantly higher in the 
DPN group (p < 0.05; Fig. 11 C). 
TPH2 mRNA expression in the rostral DRN was not elevated by DPN. In 
contrast, all rostral DRN-subregions were found to express slightly less TPH2 
mRNA than vehicle controls (Table 3). This was also consistent throughout both 
types of image analysis. Fig. 12 displays representative dark-field 
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photomicrographs of TPH2 mRNA hybridization in the DRN of systemically DPN- 
or vehicle-treated rats. 
  
Evaluation of ISH and placement of wax pellets flanking the DRN 
 To identify individual cells for the single-cell-analysis of TPH2 mRNA 
expression tissue was cresyl-violet-counterstained at an intensity sufficient  to 
label the nucleus, but not dark enough to interfere with the counting and 
identification of silver grains. As shown in Fig. 13, cell nuclei could be easily 
identified (Fig. 13 C). 
 Fig. 13 also shows original bright-field (A) and dark-field (B) 
photomicrographs of the bilaterally implanted wax pellets placed to flank the 
DRN. A schematic of actual bilateral wax pellet localization in the brainstem of all 
animals in experiment 2 is depicted in Fig. 13 D. If the center of any of the two 
pellet was found to be more than 0.5 µm away from the midline of the DRN, the 
respective animal was excluded from all data analysis. This was true for one 
vehicle-treated rat (black dots, Fig. 13 D), which reduced the size of this group 
from 10 to 9 animals.  
 
Local ERbeta activation further potentiates DPN’s effect on TPH2 expression  
 When individual subregional area-values (Table 4 A) of TPH2 mRNA 
expression in the rostral, mid-, and caudal DRN were summarized (Fig. 14 A), it 
became apparent that local DPN-treatment had more than doubled the 
expression of TPH2 mRNA in the entire caudal DRN, compared to vehicle 
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(F3,32=6.040; p < 0.01) and unoperated controls (p < 0.05). In detail (Table 4 A), a 
more than 3-fold increase of the enzyme’s expression in the dorso-caudal 
(F3,32=13.720; p < 0.01) and a 2-fold increase in the ventro-caudal DRN 
(F3,32=14.962; p < 0.05) had occurred, compared to vehicle-treated animals. In 
the dorso-mid DRN, local DPN-administration had also elevated TPH2 mRNA 
expression to about 2.5-fold of the amount expressed in vehicle controls (Table 4 
A; F3,32=18.197; p < 0.01), resulting in an about 1.7–fold overall increase of TPH2 
mRNA expression in the entire mid-DRN, compared to vehicle- and unoperated 
controls (Fig.14 A; F3,32=9.096; both p < 0.01).  
Intensity-analysis (Fig. 14 B) revealed similar results as the area-analysis, 
regarding TPH2 mRNA expression in the rostral, mid- (F3,32=5.830) and caudal 
(F3,32=7.020) DRN after local DPN-treatment. In detail (Table 4 B), the average 
single-cell intensity within the dorso- (F3,32=9.720) and ventro-mid DRN 
(F3,32=5.502), as well as the dorso- (F3,32=9.708) and ventro-caudal DRN 
(F3,32=8.070) was significantly elevated, compared to vehicle-controls and - with 
exception of the ventro-mid DRN - versus E-treated animals (p < 0.01 each).  
TPH2 mRNA expression in the rostral DRN was not elevated by DPN. 
Rather, all rostral DRN-subregions were found to express slightly less TPH2 
mRNA than vehicle controls and E-treated animals. This was also consistent 
between the two types of analyses.  
E-treated rats displayed similar, but weaker (p < 0.05 each) overall effects 
on TPH2 mRNA expression as the DPN group (Fig. 14 A: area-analysis of the 
mid-DRN F3,32=7.902; Fig 14 B: intensity-analysis of the mid-DRN F3,32=3.870, 
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and for the caudal DRN F3,32=4.090). In specific, E significantly (p < 0.05 each) 
elevated the enzyme’s expression in the dorso-mid (area-analysis: F3,32=10.007; 
intensity-analysis: F=5.202) and in the dorso-caudal DRN (intensity-analysis: 
F3,32=7.763), compared to the vehicle-treated group (Table 4 A and B). 
Fig. 15 shows representative dark-field photomicrographs of TPH2 mRNA 
hybridization in the brainstem of locally DPN-, E-, or  vehicle-treated rats.
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 Delta weight (day 8 minus day 1)  
 
C (unoperated 
controls) (7)  
Vehicle (8) 
             (9) 
 
E  
   (10) 
 
DPN  (8) 
        (10) 
 
Study I systemic treatment n.a.  25.16 ± 2.79  n.a.  31.17 ± 3.90  
Study II local treatment 28.57 ± 1.87    25.00 ± 2.21 25.80 ± 3.30 30.50 ± 2.25 
 
 
Weight gain between day 1 and day 8 of all animals used in study I (systemic, 
subcutane delivery of DPN versus vehicle) and study II (local, intracerebral 
application of DPN, estradiol (E) or vehicle. Numbers in parenthesis indicate 
group size of first (upper number) and second experiment (lower number). 































Figure 8. Systemic (subcutane) delivery of ERbeta agonist DPN was anxiolytic 
when animals were tested on the elevated plus maze (EPM, A) and in the open 
field (OF, B). Panel A displays the percent time the animals spent in the open 
arms of the EPM, the latency until the first open arm entry, the number of open 
arm entries and the number of closed arm entries (left to right). Panel B shows 
the number of rears at the walls of the OF, the time the animals spent in the 
center squares, and the total number of square line crossings. Each column 
represents the group mean ± SEM. Numbers in parentheses indicate group size. 
* (p < 0.05) and ** (p < 0.01) indicate significant differences versus vehicle 


















































































































































































































































































































































































































Figure 9.  Effect of local (wax pellet-mediated) DPN- or E-treatment on behavior 
on the elevated plus maze (EPM, panel A) and the open field (OF, panel B), 
compared to vehicle control animals. Panel A displays (left to right) the percent 
time the animals spent in the open arms of the EPM, the latency until the first 
open arm entry, the number of open arm entries and the number of closed arm 
entries. Panel B shows the number of rears at the walls of the OF, the time the 
animals spent in the center squares, and the total number of square line 
crossings. Each column represents the mean ± SEM for 9-10 animals per group. 
Numbers in parentheses indicate group size. No significant differences were 
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Figure 10.  Effects of local (wax pellet-mediated) E- and DPN-treatment of 
female OVX rats in the forced swim test. Time spent floating (left), struggling 
(middle) and paddling (right) are shown. Each column represents the mean ± 
SEM for 9-10 animals per group. Numbers in parentheses indicate group size. * 
indicates significant difference (p<0.05) versus vehicle controls;  #  indicates 
significant difference (p<0.05) versus the E-treated group. ANOVA, factor 
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Figure 11.  Systemic (subcutane) DPN-treatment of OVX females significantly 
enhanced the expression of TPH2 mRNA in the caudal,  but not in the rostral 
DRN, compared to vehicle controls. All columns represent means ± SEM of n=8 
per group. * (p < 0.05) and ** (p < 0.01) indicate significance versus respective 
vehicle controls (Mann-Whitney-U test). Two types of analyses were used to 
measure TPH2 mRNA expression. A: Results of the area-based analysis of 
TPH2 expression in the rostral, mid and caudal DRN of s.c. DPN- or vehicle-
treated rats. B: Schematic representation of the area-analysis of TPH2 
expression. The area of black pixels2 in each of the subregions of the DRN (gray 
matrices) was measured in inverted, normalized dark-field pictures of the 






















































































































































pixels (pixels2) in the rostral, mid and caudal DRN. dm = dorso-mid DRN, vm = 
ventro-mid DRN, lat-m = lateral mid-DRN. For individual subregional values see 
Table 3. Scale bar: 40 µm. C: Results of the intensity-based analysis of TPH2 
mRNA expression in the rostral, mid and caudal DRN of s.c. DPN- or vehicle-
treated rats. D: The intensity-analysis evaluated the average single-cell TPH2 
mRNA expression per subregion (gray matrices) by measuring the intensity of 
the reflected light. All cells were selected randomly (only cells lying on cross lines 
of the white grid were analyzed). For individual subregional values see Table 3. 
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Table 3 
Systemic delivery of DPN increases TPH2 expression in DRN subregions  
 
 
Part A lists individual subregion-specific values for TPH2 mRNA expression in 
the DRN, determined via area analysis [pixel2]. Part B lists individual subregion-
specific values for TPH2 mRNA expression, using single-cell analysis [pixel-
intensity]. Animals were treated subcutaneously with DPN or vehicle. Each value 
listed represents the  mean ± SEM. Numbers in parentheses indicate group size. 
* (p < 0.05)  and  ** (p < 0.01) indicate significance versus vehicle controls. 
Mann-Whitney-U test was performed between the two groups for all regions.  
 
 
 TPH2 mRNA expression per area [pixel2]  
DRN subregion  Vehicle (n=8)  DPN (n=8)  
dorso-rostral  8100 ± 1260  6158 ± 1194  
ventro-rostral  10214 ± 1382 9872 ±1394 
dorso-mid  7808 ± 721 10710 ± 1105 * 
ventro-mid  30810 ± 3515 34065 ± 2546 
lateral mid  6574 ± 960 6123 ± 666 
dorso-caudal  5120 ± 768 9965 ± 1931 * 
ventro-caudal  6220 ± 831 10602 ± 1250 * 
 
 
Average TPH2 mRNA expression per cell  
[pixel-intensity]  
DRN subregion  Vehicle (n=8)  DPN (n=8)  
dorso-rostral  143.3 ± 10.4  135.9 ± 3.3  
ventro-rostral  141.8 ± 21.3 126.0 ± 7.1 
dorso-mid  207.0 ± 6.5 242.2 ± 4.2 ** 
ventro-mid  233.1 ± 15.8 239.4 ± 5.7 
lateral mid  191.3 ± 3.3 198.6 ± 6.6 
dorso-caudal  142.4 ± 6.7 170.6 ± 5.9 ** 

















Figure 12. Representative dark-field pictures of TPH2 mRNA in the rostral (left 
side, bregma –7.3), mid- (middle, bregma –8.0), and caudal DRN (right side, 
bregma –8.7) of subcutaneously vehicle- or DPN-treated OVX animals. Vehicle-
treated animals are shown in the top row of panels, DPN-treated rats in the lower 
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Figure 13. Localization of wax pellets implanted in experiment 2. Wax pellets 
containing 0.5 µM DPN or 0.5 µM E were stereotaxically implanted left and right 
of the DRN. Bright-field (A) and dark-field (B, scale bar: 80 µm) images of 
silvergrain-labeled (small black grains) cells hybridized with a riboprobe detecting 
TPH2 mRNA, counterstained with cresyl-violet (purple), are shown. C: 
Magnification of the small square from picture A (scale bar: 40 µm). The filled 
arrow points to a silvergrain cluster above a cell nucleus (purple), the unfilled 
arrow points to a silvergrain cluster without an underlying nucleus. All single cell 
values for TPH2 expression were validated via positive nuclear (purple) 
counterstaining.  The minimum spread of a compound diffusing from the pellet 
was estimated to be 0.5 mm (Lund et al. 2006). D: Schematic picture of the rat 
brainstem at Bregma -7.80 mm (Paxinos & Watson 1998). Each gray dot 
represents the center of an implanted wax pellet. The two black dots were 
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Figure 14. Local DPN- and E-pellets flanking the DRN in female OVX rats 
elevated the expression of TPH2 mRNA in the mid- and caudal DRN. Panel A 
shows data retrieved from area analysis. Panel B shows data retrieved from 
single-cell analysis. Each bar represents the mean ± SEM. Numbers in 
parentheses indicate group size. * (p<0.05) and ** (p<0.01) indicate significant 
differences versus vehicle controls;  # (p<0.05) and ## (p<0.01) indicate 
significance versus the E-treated group; + (p<0.05) and ++ (p<0.01) versus 
unoperated control animals (C). ANOVA, factor treatment, was performed, 
followed by Tukey’s post hoc test where appropriate. For individual subregional 
values see Table 4. 
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Table 4 




Part A lists individual subregion-specific values for TPH2 mRNA expression in 
the DRN, determined via area analysis [pixel2]. Part B lists individual subregion-
specific values for TPH2 mRNA expression, using single-cell analysis [pixel-
intensity]. Each value listed represents the mean ± SEM. Numbers in 
parentheses indicate group size. * (p < 0.05)  and  ** (p < 0.01) indicate 
significance versus vehicle controls. ## (p < 0.01) indicates significance versus 
the E-treated group. TPH2 mRNA expression levels did not differ for any 
subregion between the vehicle- and the unoperated control group (data not 
shown). ANOVA, factor treatment, was performed, followed by Tukey’s post hoc 
test where appropriate.  
 
TPH2 mRNA expression per area [pixel2]  
DRN subregion  Vehicle (n=9)  E (n=10)  DPN (n=10)  
dorso-rostral   7836 ± 1013  12545 ± 3987  5927 ± 1273  
ventro-rostral 8921 ± 1650 10182 ± 732 7454 ± 2644 
dorso-mid 9165 ± 1016 16324 ± 1231 * 24110 ± 2513 **
, ##
 
ventro-mid 28029 ± 2797 34554 ± 3095 35116 ± 3535  
lateral mid 5747 ± 1810 10352 ± 1948 12074 ± 3598 
dorso-caudal 6162 ± 1055 16707 ± 4872  20138 ± 4831 ** 
ventro-caudal 8461 ± 577 11847 ± 2342 17061 ± 3283 * 
 Average TPH2 mRNA expression per cell  
[pixel-intensity]  
DRN subregion  Vehicle (n=9)  E (n=10)  DPN (n=10)  
dorso-rostral  138 ± 21.0  158 ± 15.3  110 ± 32.0  
ventro-rostral 150 ± 7.8 155 ± 11.4 121 ± 19.4 
dorso-mid 132 ± 11.1 166 ± 13.8 * 213 ±  9.8 **
, ##
 
ventro-mid 138 ± 11.9 154 ± 3.3 193 ± 29.2 * 
lateral mid 129 ± 22.5 153 ± 10.7 201 ± 37.9 
dorso-caudal 140 ± 16.6 197 ±  7,4 * 238 ± 17.0 **
, ##
 


























Figure 15. Representative dark-field pictures of silvergrain-labeled cells 
expressing TPH2 mRNA in the rostral (left side, bregma –7.3), mid- (middle, 
bregma –8.0) and caudal DRN (right side, bregma –8.7) of locally vehicle-, E- or 
DPN-treated female OVX animals. Vehicle-treated animals are shown in the top 
row of panels, E-treated rats in the middle row of panels, and DPN-treated rats in 




(Bregma – 8.7) 
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Our results show that, compared to vehicle controls, both systemic and 
local activation of ERbeta in or around the DRN increased the expression of 5-
HT-neuronal TPH2 mRNA in a subregion-dependent manner. Estrogen treatment 
resulted in similar overall effects, but to a lesser extent than DPN. Furthermore, 
animals treated locally with DPN or E showed decreased despair-like behavior. 
However, only systemic delivery of DPN decreased anxiety-like behavior, while 
local administration of the ERbeta-selective compound failed to have the same 
effect. This indicates that ERbeta actions within the DRN are sufficient to 
regulate despair-like behavior, but that other brain circuitries are necessary to 
control anxiety-like behavior. 
The observed DPN- or estrogen-induced increase in TPH2 mRNA 
expression was mainly restricted to the dorso-mid and the caudal DRN. These 
findings are consistent with observations by Hiroi et al. (2006), who reported 
elevated TPH2 mRNA expression specifically in the dorso- and ventro-caudal 
DRN following systemic estrogen treatment in female OVX rats. Furthermore, 
recent studies in rats and mice indicate that depression-related paradigms 
(Keeney and Hogg, 1999; Becker et al., 2007) like social defeat (Gardner et al., 
2005) or inescapable stress (Grahn et al., 1999; Amat et al., 2005) selectively 
activate the dorsal and caudal parts of the DRN, subregions that give rise to 
projections targeting forebrain areas involved in the control of emotional behavior 
(Lowry et al., 2005; Lowry et al., 2008). The mid-dorsal DRN, for instance, sends 
out collateral projections to emotion- and stress-related brain areas (Lowry, 
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2002). These branched projections could, for instance, simultaneously modulate 
the hypothalamic PVN and the central amygdala (CeA). 5-HT axons from the 
caudal DRN target limbic structures like the hippocampus, the entorhinal cortex 
and the septum (Kohler et al., 1982; Kohler and Steinbusch, 1982), indicating 
that an alteration in TPH2 expression and 5-HT neurotransmission by estrogens 
may improve memory and learning deficits that are associated with depression 
(Shors et al., 1998; Burriss et al., 2008; Liu et al., 2008). Within the entire caudal 
DRN it is again the dorso-caudal subdivision that has been suggested to play a 
crucial role in affective disorders (Commons et al., 2003). In clinical studies of 
drug-free, depressed suicide victims, exactly those dorso-caudal DRN 
subregions exhibited elevated TPH2 protein and mRNA expression (Bonkale et 
al., 2006; Bach-Mizrachi et al., 2008). However, while a pathological increase in 
TPH2 expression may reflect a compensatory feedback response to low overall 
5-HT concentrations in the brain of depressed patients (Mann et al., 1989; 
Owens and Nemeroff, 1994; Placidi et al., 2001), therapeutic up-regulation of 
TPH2 may be beneficial, ultimately boosting 5-HT neurotransmission. More 
detailed studies in animal models, quantifying TPH2 protein and local 5-HT 
release and turnover within the DRN itself (autoregulation) and in target areas, 
are required to address this issue satisfactorily. 
In our experiments, systemic delivery of DPN resulted in reduced anxiety-
like behavior, confirming the anxiolytic nature of ERbeta (Krezel et al., 2001; 
Imwalle et al., 2005; Lund et al., 2005; Rocha et al., 2005; Walf and Frye, 2007a, 
b; Walf et al., 2008a). In contrast, local DPN- or estrogen-treatment at the raphe 
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nuclei failed to decrease anxiety-like behavior, indicating that anxiety-regulation 
may primarily involve other brain areas, such as the hypothalamic PVN (Herman 
et al., 2002a; Donner et al., 2007; Blume et al., 2008; Neumann, 2008), the 
lateral septum (Henry et al., 2006), the amygdala (Bosch et al., 2007), and the 
bed nucleus of the stria terminalis (Davis et al., 1997; Walker et al., 2003).  
Our studies demonstrate, however, that local delivery of DPN or estrogen 
is sufficient to decrease despair-like behavior. While recent studies revealed an 
antidepressant function of ERbeta (Walf et al., 2004; Rocha et al., 2005; Hughes 
et al., 2008), our experiments suggest a concrete site of action for the observed 
effect. Thus, high anxiety and despair-like behavior may be closely related 
regarding the phenotype of depression (Chaby et al., 1993; Leibbrand et al., 
1999; Farabaugh et al., 2005; Godart et al., 2006; Mittal et al., 2006), but they 
may be two distinct mental states in their neuroanatomical origin. The fact that 
estrogen-treated rats in our experiment spent more time immobile / floating in the 
FST than their DPN-treated counterparts contradicts previous studies in mice 
and rats, which found that DPN and estrogen generally decrease the time spent 
immobile during the FST (Walf et al., 2004; Rocha et al., 2005). However, our 
study delivered estrogen locally via wax pellets flanking the DRN, whereas the 
mentioned other reports administered estrogen and DPN systemically. It is 
unclear at this point, why the behavioral effects of DPN or estrogen differ into 
opposing directions in this particular parameter. In accordance with previous 
studies (Walf et al., 2004; Rocha et al., 2005), both estrogen and DPN did, 
indeed, increase the time rats spent actively struggling during the FST. Further 
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studies will have to confirm if, and explore how, ERbeta-mediated elevation of 
TPH2 mRNA expression in the mid-dorsal and caudal DRN, actually causes an 
attenuation of despair behavior. 
Overall, local estrogen-treatment had similar, but less intense effects on 
TPH2 mRNA expression and on despair-like behavior than the selective ERbeta 
agonist. This gradual difference may be explained with a simultaneous action of 
estrogen on both ERalpha and ERbeta, and with the suggested opposing 
functions of the two ER types (Couse et al., 2000; Pike et al., 2000; Shapiro et 
al., 2000; Liu et al., 2002; Lindberg et al., 2003; Toufexis et al., 2007). While 
increased ERalpha mRNA and single nucleotide polymorphisms (SNPs) in the 
gene coding for ERalpha are associated with mental illness, specifically with 
depression (Perlman et al., 2005; Mill et al., 2008), ERbeta-mediated actions 
have been found to exert anxiolytic and antidepressant effects in various animal 
models (Krezel et al., 2001; Imwalle et al., 2005; Lund et al., 2005; Rocha et al., 
2005; Walf and Frye, 2007a, b; Walf et al., 2008b). Estrogen itself binds to both 
receptor types with about the same affinity (Kuiper et al., 1997; Lund et al., 
2005), and could, thus, activate two functionally opposing mechanisms, both 
ultimately balancing TPH2 mRNA expression and emotionality.  
Immunohistochemical receptor localization studies have found both 
ERbeta1 (Lu et al., 2001) and ERbeta2 (Chung et al., 2007), a novel splice 
variant carrying an 18-amino acid insert between the fifth and the sixth exon in 
the ligand-binding domain, in the DRN of female rats. However, due to quality 
differences in antibodies used for immunohistochemical studies of ERbeta, the 
 69
exact expression pattern of ERbeta and its splice variants in the rat DRN is still 
controversial (Sheng et al., 2004). In mice, Nomura et al. (2005) revealed that 
ERbeta, but not ERalpha is located within 5-HT neurons. In rat, we also 
hypothize that ERbeta (Lu et al., 2001) and possibly splice variants of ERbeta 
(Chung et al., 2007) are expressed within 5-HT neurons of the DRN. Based on 
preliminary studies in our lab (data not shown), ERalpha may only be expressed 
in local non-5-HT-, but possibly GABAergic (Hart et al., 2001; Su et al., 2001) 
neurons, indicating that ERalpha could interfere with the negative feedback loop 
(Haddjeri et al., 2000; Liu et al., 2000) regulating 5-HT-neuronal function.  
Differences in the expression of ERalpha versus ERbeta in the midbrain of 
rats (Shughrue et al., 1997a; Shughrue et al., 1997b; Lu et al., 2001), mice 
(Nomura et al., 2005; Vanderhorst et al., 2005), guinea pigs (Lu et al., 1999; 
Warembourg and Leroy, 2004), and cats (VanderHorst et al., 1998) generally 
evoke the notion that profound species differences may exist regarding the 
modulation of the 5-HT system by gonadal steroids. While ERbeta seems to be 
the predominant ER to be expressed in the 5-HT-neural DRN of rodents, ERbeta 
expression in the human DRN remains to be investigated, but is likely, since 
ERbeta mRNA levels also dominate over ERalpha in the DRN of primates 
(Gundlah et al., 2000; Gundlah et al., 2001). ERbeta may, thus, directly and 
positively regulate TPH2 gene transcription.  
The molecular or neurotransmitter-mediated mechanisms by which 
ERbeta and ERalpha may directly or indirectly modulate TPH2 gene expression 
are still unknown. Most ER-induced changes in gene transcription are due to 
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classic effects of the steroid receptors acting as nuclear transcription factors. 
More and more studies, however, discover rapid, non-genomic mechanisms of 
ER action within the cell (Cato et al., 2002; Mhyre and Dorsa, 2006; Levin, 2008).  
The observation that local estrogen-treatment significantly increased 
TPH2 in the mid-dorsal and in the caudal DRN, raises the question whether 
physiological changes of circulating estrogen concentrations in cycling women 
have similar effects, and if, for example, an abnormal ratio of ERalpha versus 
ERbeta expression or a disruption of normal ER-regulation of TPH2 expression 
in the midbrain contribute to severe menstrual mood disorders like the 
premenstrual syndrome (Rubinow, 1992; Arpels, 1996; Schmidt et al., 1998) or  
premenstrual dysphoric disorder (Gorman, 2006). Our results further elucidate 
the roles that ERbeta and ERalpha may play in the regulation of mood disorders 
in females. Considering the clinical relevance of an intact system for 5-HT 
production (Zill et al., 2004; Zhang et al., 2005; Bach-Mizrachi et al., 2008) and 
the importance to address the sex ratio in depressive disorders (Kornstein et al., 
1995; Grigoriadis and Robinson, 2007), our studies may also help to develop 
sex-specific treatment of depression (Gorman, 2006).  
In conclusion, our results confirmed the hypothesis that chronic, local 
activation of ERbeta alters TPH2 mRNA expression in the DRN in a subregion-
dependent manner, and, at the same time, changes emotion-related behavior. 5-
HT neurons of the DRN may be the key regulators of despair-like behavior, 
whereas other brain circuitries seem to be necessary to alter anxiety-related 
behavior. 
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CHAPTER 4  
DISCUSSION  
The goal of these studies was to determine the role of estrogen receptors 
for the regulation of TPH2 within 5-HT neurons of the DRN. Four main findings 
were derived. First, local ERbeta activation within the midbrain is sufficient to 
decrease despair-like behavior in female OVX rats. Second, local ERbeta 
activation does not decrease anxiety-like behavior, whereas systemic activation 
does. Third, systemic, as well as local ERbeta activation elevates TPH2 mRNA 
expression in a subregion-dependent manner, with local treatment being more 
efficient than peripheral s.c. administration; and fourth, local administration of 
estradiol exerts similar effects on TPH2 mRNA expression and behavior as does 
DPN, but to a lesser extent. While each individual result is discussed in detail the 
last part of the previous chapter, I will broaden the discussion further and explore 
potential mechanisms of action, ways for signal transmission and mood 
regulation, estrogen receptor splice variants, involvement of other steroid 
receptors, and possible future research directions in this chapter. 
A functional, well-balanced system for 5-HT production is essential for 
mental health, and at the core of this system acts TPH2, the rate-limiting enzyme 
for 5-HT synthesis in the brain (Walther et al., 2003). When this system gets out 
of balance, either due to a mutation in the TPH2 gene (Sun et al., 2004; Zill et al., 
2004; De Luca et al., 2005; Shink et al., 2005; You et al., 2005; Zhang et al., 
2005; Harvey et al., 2007; Lim et al., 2007; Lopez de Lara et al., 2007; Maron et 
al., 2007; Haghighi et al., 2008) or, often in correlation, due to an abnormal 
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mRNA and protein level of TPH2 (Boldrini et al., 2005; Bach-Mizrachi et al., 
2006; Bonkale et al., 2006; Lim et al., 2007; Bach-Mizrachi et al., 2008), it may 
change 5-HT release in target areas, 5-HT turnover and feedback regulation, as 
well as 5-HT auto- and target cell receptor densities. Depending on the 
subdivision of the DRN, 5-HT axons from the DRN innervate many different 
forebrain areas (Lowry et al., 2008). Thus, it is not surprising that these 
subdivisions can react differently to the same stimulus, in my experiments an 
ERbeta-selective agonist. Other interesting questions are 1) what ER splice 
variants are involved and where are they located, 2) upon ERbeta activation, 
what are the neuronal circuits and changes within synapses on the way from the 
DRN to target neurons, and 3) what are the intracellular mechanisms in 5-HT 
neurons that ultimately lead to an ERbeta-mediated alteration in TPH2 
transcription?     
Based on results from our and other laboratories (Shughrue et al., 1997a; 
Lu et al., 2001), ERbeta seems to be the predominant ER that is expressed in 5-
HT neurons of the rat DRN, and is likely to regulate TPH2 gene expression 
directly through classic genomic actions. So far, however, an ERE in the TPH2 
promoter sequence has not been discovered. Nonetheless, ERbeta could 
interact with numerous other transcription factors or transcription-enhancing 
proteins to increase the expression of TPH2. The gradually attenuated effect of 
estrogen on TPH2 expression compared to DPN-treatment could suggest an 
opposing action of ERalpha, as seen in other tissues (Couse et al., 2000; Liu et 
al., 2002). However, in rat, none or only miniscule immunoreactivity for ERalpha 
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has been reported within the DRN (Shughrue et al., 1997a; Sheng et al., 2004), 
and dual-ICC studies from our lab confirm the lack of ERalpha in brainstem 
TPH2 neurons. Instead, a high density of intense ERalpha-immunoreactive cells 
is localized within the periaqueductal gray (PAG) dorsal of the DRN (Murphy et 
al., 1999; Loyd and Murphy, 2008), and some ERalpha-positive cells are found 
within the lateral DRN, often adjacent to TPH2 neurons, but never colocalized 
with TPH2 (unpublished results). ERalpha could, for example, be expressed in 
the nuclei of PAG-typical cholinergic neurons, which are especially active during 
social defeat, an animal paradigm for depression (Kroes et al., 2007). If those 
neurons actually project onto 5-HT neurons of the DRN, varying levels of 
circulating estrogen (and thus also estrogen-levels in the brain), could indirectly 
influence the activity of TPH2 expression. ERalpha could also be invoked in brain 
regions farther away, such as the hypothalamic PVN, which not only receives 
input from the DRN, but also sends out projections towards the DRN (Abrams et 
al., 2004; Lowry et al., 2008)  In another dual-ICC study, I identified some 
ERalpha-positive neurons in and around the lateral DRN to be positive for 
glutamic acid decarboxylase, a marker for GABAergic neurons. Since GABA is 
the brain’s most important inhibitory neurotransmitter, this might indicate that 
ERalpha can enhance the inhibitory input towards the DRN, possibly interacting 
with negative feedback loops that control the DRN (Liu et al., 2000; Tao and 
Auerbach, 2003). Identification of ERalpha in GABAergic interneurons of the 
hippocampus corroborates the concept that ERalpha may enhance GABAergic 
neurotransmission (Hart et al., 2001; Su et al., 2001). Fig. 16 displays a 
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schematic model for these predicted inhibitory afferents of the DRN, and for 
relative expression levels of ERalpha and ERbeta depending on the rostro-
caudal and ventro-dorsal axes of the DRN. 
Depending on the nature of the postsynaptic 5-HT receptors, 5-HT can be 
either inhibitory or excitatory towards the target neuron. Most efferents from the 
DRN  to the forebrain are indirect. For instance, 5-HT projections from the dorso-
mid DRN mainly target glutaminergic neurons surrounding the hypothalamic 
PVN. Increased 5-HT release onto those excitatory neurons could, thus, 
indirectly inhibit the stress-reactivity of the PVN via an inhibition-of-excitation 
principle (Herman et al., 2002b). This hypothesis is corroborated by the fact that, 
in humans, depression is commonly characterized by a hyperactive HPA axis 
and hypercortisolemia (Gillespie and Nemeroff, 2005).  
Most current antidepressant-treatments target the 5-HT reuptake 
mechanism via SSRIs, and are based on the so-called “receptor theory” of 
depression, asserting that each drug must ultimately change postsynaptic 
receptor expression and signaling pathways before it is effective. The same 
reasoning is used for the typical one- to two-week delay before the patient 
recognizes an improved state of mind (Cowen and Sargent, 1997; Wilson, 2007). 
Nonetheless, boosting the 5-HT system directly by enhancing mRNA and 
presumably protein levels of TPH2, offers an alternative or additional therapeutic 
tool, especially if low expression of this enzyme is the cause and core of the 
pathology. A recent study showed that the SSRI-antidepressant fluoxetine 
ultimately also resulted in upregulated TPH2 expression (Shishkina et al., 2007). 
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A combinatory treatment of depression using common SSRIs together with 
TPH2-targeting drugs may be beneficial. 
Projections from the caudal DRN, the subdivision where I noticed the most 
profound elevation of TPH2 expression after DPN- or estrogen-treatment, target 
limbic structures like the hippocampus, the septum and the entorhinal cortex 
(Abrams et al., 2004). With regard to depression-induced learning- and memory-
deficits reaching all the way to severe debilitation of intellectual performance 
(Horan et al., 1997; Shors et al., 1998; Basso and Bornstein, 1999; Burt et al., 
2000; Rose and Ebmeier, 2006; Burriss et al., 2008), this is of particular interest. 
Importantly, stress- and depression-induced performance deficits in women, but 
not in men, and in female animals, but not in males, are one of the most obvious 
and remarkable sex differences in depressive disorders (Shors and Leuner, 
2003). In the cerebellum, ERbeta seems to enhance the induction of synaptic 
long-term potentiation, and to improve motor-related memory (Andreescu et al., 
2007). Within the hippocampus, ERbeta has also been shown to improve 
memory and stimulate synaptic plasticity (Liu et al., 2008). Thus, it is quite 
possible that ERbeta-induced elevation of TPH2 mRNA expression in the caudal 
DRN may cause increased 5-HT neurotransmission towards the hippocampus, 
resulting in improved memory consolidation or storage. Future studies should 









Figure 16. Schematic illustration of proposed neuroanatomical afferents to the 
rostro-caudally oriented subdivisions of the DRN, suggesting opposing actions of 
ERalpha and ERbeta on TPH2-neuronal function. Font size represents relative 
levels of receptor expression. GABA = gamma-aminobutyric acid, dr=dorso-
rostral, vr=ventro-rostral, dm=dorso-mid, vm-ventro-mid, lm=lateral mid, 
dc=dorso-caudal, vc=ventro-caudal. 
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The intracellular and / or nuclear mechanism by which ERbeta regulates 
the expression of TPH2 mRNA remains to be revealed. Most likely, following 
ligand binding, ERbeta acts as a classic steroid hormone receptor, initiating 
transcription at a response element on the DNA, activating and collecting other 
transcription factors into an initiation (of transcription) complex, ultimately causing 
a signaling cascade that leads to DNA remodeling and TPH2 promoter activation.  
In the dorsal raphe, the expression of TPH1, the non-brain-specific version 
of the enzyme which is only expressed at very low levels in the brain (Malek et 
al., 2005; Abumaria et al., 2008), is regulated by cAMP (Boularand et al., 1995), 
indicating a regulatory effect of CREB (cAMP response element binding protein) 
on TPH1 transcription. It needs to be determined, if the control of TPH2 gene 
expression works in a similar way. The many options of posttranscriptional or 
posttranslational modifications of the enzyme’s activity must also be considered.  
Elevated TPH2 expression is likely but not guaranteed to result in elevated 
enzyme concentration in the neuron; and that, again, does not necessarily mean 
that the enzyme always possesses the same activity. In contrast to TPH1, TPH2 
contains an additional 41 amino acids at the N-terminus. Murphy et al. (2008) 
revealed that amino acids 10-20 in this N-terminal region of TPH2 carry an 
important sequence that normally keeps the enzyme’s expression at relatively 
low levels. When this region is removed, TPH2 mRNA expression increases. 
Another modification of the enzyme’s activity is posttranslational phosphorylation.  
Phosphorylation of serine 19, a protein kinase A consensus site located in the 
same N-terminal domain, leads to increased stability of TPH2, and consequently 
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increases the 5-HT output of the enzyme (Murphy et al., 2008). Thus, it would be 
of interest to investigate whether non-genomic, rapid signaling actions of other 
membrane-bound or cytosolic ERs regulate TPH2 activity at the protein level. 
In rat, it is still unclear exactly which DRN cell population contains 
ERalpha or ERbeta and what splice variants that concerns. However, there is 
reason to believe that the DRN contains novel splice variants of ERbeta in 
addition to the already detected ERbeta2 (Chung et al., 2007). My hypothesis is 
that the origin of the controversial results regarding the presence or absence of 
ERbeta in the rat DRN lies in a C-terminal truncation of the receptor in this 
particular brain region. The antibodies against ERbeta were all created to detect 
one or several epitopes along the C-terminal ligand-binding domain. Thus, the 
reason as to why I can identify high expression levels of ERbeta mRNA with RT-
PCR (preliminary results), but some otherwise very reliable antibodies do not 
detect ERbeta protein (Sheng et al., 2004) in the rat DRN, may be explained with 
one or more novel splice variant mRNAs lacking some part of the C-terminus 
(Fig. 17). If such variants existed, the consequence on the binding affinity of 
various ligands, including estrogen and DPN, would need to be determined for 
each novel ERbeta variant. Possibly, certain subregions of the DRN may express 
only one or the other subset of ERbeta splice variants. A unique expression 
pattern like that could further explain the subregion-dependent regulation of 
TPH2 mRNA expression, which was observed in the work presented. At this 
point, however, these proposed truncated splice variants are purely hypothetical. 
Therefore, a future study could be to characterize via RT-PCR the expression 
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pattern of ERs in the DRN of OVX rats without treatment, and of OVX rats with 
chronic systemic estradiol-substitution, in order to assess potential effects of 




Figure 17. Proposed C-terminal truncation of ERbeta in the DRN. “X” represents 












 The overall conclusion of this thesis is that ERbeta regulates the 
expression of TPH2 mRNA within selective subdivisions of 5-HT neurons in the 
female rat DRN, and that this is correlated with decreased despair-, but not 
anxiety-like behavior. Future studies will have to address the molecular 
mechanism of transcriptional modulation through ERbeta, which splice variants 
are expressed and translated within each subdivision of the DRN, and if an 
increase in TPH2 mRNA expression actually results in elevated TPH2 protein, 5-







LIST OF ABBREVIATIONS 
 
5-HT 5-hydroxytryptamine / serotonin 
[35S]-UTP radioactively labeled uridine-triphosphate 
α  alpha 
αERKO ERalpha knock-out (mouse), ERalpha null mutation 
β  beta 
βERKO ERbeta knock-out (mouse), ERbeta null mutation 
δ delta; indicates a missing exon, created by alternative splicing 
AAALAC Association for Assessment and Accreditation of Laboratory Animal Care 
AADC  aromatic amino acid decarboxylase 
ANOVA analysis of variance 
BH4 tetrahydrobiopterin 
BLAST Basic Local Alignment Search Tool 
C unoperated control group; OR: C- = carboxy- (terminus) 
Ca2+ Calcium ion 
cAMP cyclic andosine-monophosphate 
cDNA complementary DNA 
CeA central amygdala 
CREB cAMP response element binding protein 
cRNA complementary ribonucleic acid (riboprobe) 





DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
DPN diarylproprionitrile; diarylproprionitrile-treated group 
dr dorso-rostral 
DRN dorsal raphe nuclei 
E (17-beta-)estradiol; estradiol-treated group 
EDTA ethylendiaminetetraacetic acid 
EPM elevated plus maze (anxiety behavior test) 
ERalpha estrogen receptor alpha  
ERbeta estrogen receptor beta  
ERE estrogen response element  
Fe2+ iron ion 
FST forced swim test (despair behavior test) 
GABA gamma(γ)-aminobutyric acid 
GIT buffer guanidine-isothiocyanate buffer 
GPCR G-protein-coupled receptor 
3H Tritium (radioactive) 
HPA hypothalamo-pituitary-adrenal  
ICC immunocytochemistry 
ISH  in situ hybridization  
Kb kilo-bases (103)  
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Kd dissociation constant 
KCl potassium chloride 
Ki binding affinity 
LacZ beta-galactosidase 
LAT large amino acid transporter 
LBD ligand-binding domain 
lm lateral mid 
MAO monoamine oxidase 
MAOI monoamine oxidase inhibitor 
MDD major depressive disorder 
Mg2+ magnesium ion  
MgCl magnesium chloride 
MMLV-RT Moloney Murine Leukemia Virus - Reverse Transcriptase 
mRNA messenger ribonucleic acid 
n.a. not applicable 
NaCl sodium chloride 
NIH National Institutes of Health 
O2 molecular oxygen  
OF open field (anxiety behavior test) 
OVX ovariectomy / ovariectomized 
PAG periaqueductal gray 
PCR polymerase chain reaction 
PMDD  premenstrual dysphoric disorder 
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PMS  premenstrual syndrome  
PPT propylpyrazoletriol 
PVN paraventricular nucleus (of the hypothalamus) 
RT-PCR reverse transcription-polymerase chain reaction 
s.c. subcutane 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
SERT  5-HT transporter  
SNP single nucleotide polymorphism 
SSC sodium chloride with sodium citrate (buffer) 
SSRI “selective” serotonin reuptake inhibitor 
T1/2 half-life 
TA- thymine 3’-overhang (used during so called “TA-cloning”) 
Taq pol. heat-resistant DNA polymerase from thermus aquaticus  
TOPO topoisomerase  
TPH2 tryptophan hydroxylase 2 / neuronal tryptophan hydroxylase 
Tris-Cl tris base with hydrochloric acid 




WT (genetic) wild type 
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